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ABSTRACT 
 
The present investigation has been undertaken as study the anti-parkinson 
activity of aqueous extract of Barleria prionitis. The plant Barleria prionitis of 
family acanthaceae an ayurvedic herb which is known for its significant 
medical properties. Experiments were conducted following standard procedures. 
The aqueous extract of Barleria prionitis  were evaluated for their invivo 
antioxidant and anti-parkison properties and neurotransmitters level. The anti-
parkinson activity of AEBP was evaluated using MPTP induced parkinson and 
Rotenone induced Parkinson models. Levodopa was used as standard for both 
models. Extracts treated groups showed higher invivo antioxidant and anti-
parkinson activities. They also showed higher activity in neurotransmitters 
level. AEBP exhibited similar anti-parkinson activity that of standard but with 
lesser magnitude. The result may be attributed to the chemical constituents such 
as iridoid glycosides present in it which may be due to their individual or 
cumulative effect that enhanced anti-parkinson activity and provided scientific 
evidence of the ethnomedicinal futures of Barleria prionitis. These findings 
could justify the inclusion of this plant in the management of parkinson’s 
disease. 
Keywords: AEBP, anti-parkinson, MPTP, rotenone, chemical constituents.   
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1. INTRODUCTION 
1.1 INTRODUCTION 
                 This chapter present: back ground of study, statement of the problem, definition of 
terms, theoretical framework, purpose of the study,  hypothus and specific aim. 
1.1.1 BACK GROUND OF STUDY 
             Parkinson Disease (PD) is the second most chronic neurodegenerative disorder in the 
world, after Alzheimer´s Disease (AD), and is estimated to affect about 2% of the population 
over 60 years of age. The disease generally affects persons aged 55–64 years, although 
occasionally much younger individuals are affected. Although the causes for degeneration of 
dopaminergic neurons in Parkinson’s disease are not well understood, The degeneration of 
these dopaminergic neurons leads to four cardinal, debilitating symptoms: resting tremor, 
muscular rigidity, bradykinesia, and postural imbalance.
[1,2]
  
 
              At current research, the etiology of PD is still not clearly known. Evidences suggest 
massive oxidative stress leading to the formation of free radical. Pathologically the hallmark 
of Parkinson disease are the severe loss of dopaminergic neuron in the substantia nigra pars 
compacta and the presence of proteinaceous inclusion called lewy bodies, which is mainly 
composed of fibrillar α-synuclein and ubiquitinated protein with in some remaining nigral 
neurons.
[3,4]
 
 
               The plant Barleria prionitis contains Iridoids, Barlerin, Acetyl barlerin, β-sitosterol, 
Prioniside, Barlerinoside, verbascoside, 7-methoxy diderroside, Anthroquinones, Flavonoids. 
The plant used for Stomach disorder, Urinary infections, fever, Tooth ache, Diuretic, 
Jaundice, Asthma, Arthritis, Inflammation, Migraine, Dropsy, Leprosy.
[5,6]
 
 
1.1.2 STATEMENT OF PROBLEM 
                In 2015, PD affected 6.2 million people and resulted in about 117,400 deaths 
globally. Parkinson's disease typically occurs in people over the age of 60, of which about 
one percent are affected. Males are more often affected than females. When it is seen in 
people before the age of 50, it is called young-onset PD.
[7]
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                   The World Health Organization gives an "estimated crude prevalence" (the total 
number of existent cases each year, old and new) of 160 per 100,000, and an estimated 
incidence (the number of new cases each year) of 1619 per 100,000. The incidence of PD 
varies across the globe. However, this distribution may not be as simple as a geographical or 
ethnic factor. It is known that the PD is more prevalent in North America and Europe than in 
Asia and West Africa. However, research has been carried out to know the causes of PD and 
the use of medicinal plants for its treatment, prevention, and cure.
[8]
 
                    In China alone, there are more than 1.7 million people with PD. The prevalence 
of PD per 100,000 of population varies from country to country, with highest in Albania 
(800) followed by Egypt (557), USA (329107), Israel (256), Japan (19376), Germany (183), 
Spain (170122), Italy (168104), Finland (166120), Bulgaria (164137), Estonia (152), 
Australia (146104), England (139121), Portugal (135), Cuba (135), Canada (125), China 
(11957), Scotland (129), Norway (102), Thailand (95), Sweden (76), New Zealand (76), 
Nigeria (67), Poland (66), Jordan (59), etc. 
                   The Parsi community in Mumbai has the world's highest incidences of PD where 
it affects about 328 out of every 100,000 people despite living in a country, India, with one of 
the world's lowest incidence of PD (70 out of 100,000). The world's highest prevalence of 
Parkinson's Disease of any country in the world is Albania at a rate of  800 per 100,000. 
Ethiopia has the world's lowest recorded prevalence of Parkinson's Disease. At a rate of only 
7 per 100,000. 
                     There are more men than women with Parkinson's Disease. However, the ratio 
of males to females who have Parkinson's Disease differs a lot according to the country. In 
Nigeria there are far more men than women who have Parkinson's Disease. In Japan more 
women than men have Parkinson's Disease.
[9]
 
 
1.1.3 DEFINITION OF TERMS 
 
Antioxidants 
Substances found in certain foods and supplements that can remove toxic free radicals from 
the body.
[10]
 
 
 
 
 
Introduction 
 
Department of Pharmacology, KMCH College of Pharmacy  3 
 
Parkinson’s Disease 
Parkinson's Disease is the second most common progressive neurodegenerative disorder and 
Characterized by both motor and non-motor symptoms, PD patients classically display rest 
tremor, rigidity, bradykinesia, and stooping posture. PD can also be associated with 
neurobehavioral disorders (depression, anxiety), cognitive impairment (dementia), and 
autonomic dysfunction (e.g., orthostasis and hyperhidrosis).
[11]
 
Tremor 
Tremor, a rhythmic, involuntary, oscillatory movement of body parts, is the most common 
movement disorder. Tremors are classified as rest or action tremors. Rest tremor occurs when 
the affected body part is completely supported against gravity. Action tremors are produced 
by voluntary muscle contraction and are further divided into postural, isometric, or kinetic 
tremors.
[12]
 
Rigidity: Stiffness of the muscles
[13]
 
Bradykinesia: Slowness of movement; a common motor symptom of PD.
[14]
 
Postural instability        
A tendency to fall or the inability to keep oneself from falling; imbalance.
[15] 
              
Oxidative stress                                                                                                                     
Oxidative stress is the result of an imbalance in pro-oxidant/antioxidant homeostasis that     
leads to the generation of toxic reactive oxygen species (ROS), such as hydrogen peroxide, 
organic hydro peroxides, nitric oxide, superoxide and hydroxyl radicals etc.
[16]
 
Mitochondrial dysfunction 
Mitochondrial dysfunction(s) (MDs) can be defined as alterations in the mitochondria, 
including mitochondrial uncoupling, mitochondrial depolarization, inhibition of the 
mitochondrial respiratory chain, mitochondrial network fragmentation, mitochondrial or 
nuclear DNA mutations and the mitochondrial accumulation of protein aggregates.
[17]
 
Neurotransmitters                                                                                                      
Neurotransmitters are chemical messengers which are responsible for communication among 
neurons. Neurons are the cells of chemical communication in the brain.
[18]
 
Alpha-synuclein 
Alpha-synuclein (Syn), a small protein of 140 amino acids specifically enriched in the 
presynaptic nerve terminals, has been found as a major component of Lewy bodies, with 
intraneuronal inclusion present in the brain of Parkinson’s disease (PD) patients.[19] 
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Substantia nigra 
meaning “black substance” in Latin, a region in the base of the brain that contains dopamine-
producing neurons, which appear dark under a microscope; people with PD experience cell 
loss in this region.
[20]
 
MPTP 
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a prodrug to the neurotoxin MPP+, which 
causes permanent symptoms of Parkinson's disease by destroying dopaminergic neurons in 
the substantia nigra of the brain. It has been used to study disease models in various animal 
studies.
[21]
 
Rotenone                                                                                                                                  
Rotenone is an odorless chemical that is used as a broad-spectrum insecticide, piscicide, 
and pesticide. It occurs naturally in the roots and stems of several plants. It causes Parkinson's 
disease if injected into rats.
[22]
 
1.1.4 THEORETICAL BACKGROUND STUDY 
 
                      Parkinson’s disease (PD) was the first neurological disease and characterized by 
degeneration of neuromelanin-rich dopaminergic neurons in the substantia nigra pars 
compacta and the frequent deposition of Lewy bodies. Speech impairment has been reported 
in 60-80% of the PD patients which reaches up to 100% in the later stages. Lazarus et al., 
subjected PD patients to the Indian Speech and Hearing Association (ISHA) articulation 
assessment and the Vaghmi software. It was found that 64.7% had slow reading speed, 60.2% 
hoarseness of voice, 39.8% articulatory defect, and 32.3% jerky speech. 
 
                       Memory disturbances and dementia are known to occur in later stages of PD. 
Patients with early PD can have subtle disturbances in neuropsychological testing. To 
evaluate whether these abnormalities were affected by treatment, PD patients were assessed 
after 12 weeks of levodopa (LD) therapy. 
 
                        Several neuropsychiatric manifestations such as depression, anxiety, and sleep 
disturbances have been described in PD. Depression in PD may be reactive depression as a 
result of chronic illness as well as a result of neurodegeneration. 
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                         Psychosis can also be a part of nonmotor spectrum of PD. It may be disabling 
to the patients and its presence may also warrant change in treatment strategies. The 
manifestations include hallucinations and delusions. In a study from India by Amar et al., 40 
patients of PD with psychosis were assessed. Pure hallucinations were commonest in these 
patients (85%) and a combination of delusions and hallucinations was found in 7.5%. Of 
these visual hallucinations were predominant, amounting to 60%. 
 
                          Animal models are valuable tools for studying the biology and genetics of 
human parkinson as well as for preclinical investigation of anti-parkinson therapeutics and 
parkinson preventive studies. Various animal models have been generated by genetic 
engineering, graft transplantation, and viral/physical/chemical induction. Studies from animal 
models of parkinson have been utilized for preclinical investigation of therapeutic efficacy 
and toxicity of chemicals and biologicals. Tremendous advances have been made in the 
generation of animal models of parkinson, which have become increasingly sophisticated by 
application of new technologies and integration of clinical information from patients. The 
goals are to faithfully recapitulate the human parkinson diseases in the animal models and 
apply them as preclinical tools, with the hope of successfully translating the basic knowledge 
into treatment and prevention of parkinson in humans. 
                           The mouse has been the traditional animal model for basic and preclinical 
studies of parkinson, and other organisms including zebrafish play important and 
complimentary roles as models of parkinson research. Genetically engineered mouse models 
of parkinson have been generated by a variety of interventions such as chemical or physical 
mutagenesis, viral infection, insertion of transgenes, homologous recombination, and the 
recently developed gene edition. There are numerous publications of research studies 
regarding generation of animal models of parkinson and their pre-clinical applications.
[23,24] 
MPTP induced PDs 
                   1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP), is a potent neurotoxin & 
highly lipophilic. After systemic administration it rapidly crosses the blood-brain barrier, 
enters astrocytes and is metabolized to its active metabolite MPP+ by monoamine oxidase-B 
(MAO-B). MPP+ is able to inhibit complex 1 of the mitochondrial electron transport chain, 
resulting in the formation of ROS & leading to reduced ATP production. 
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                   Neuroprotection suggests preventing or slowing disease progression. 
Nevertheless, despite advances toward this goal, all current treatments are symptomatic; none 
halt or retard dopaminergic neuron degeneration. L-dopa treatment produces many 
distressing side effects, and its possible that metabolism of excess dopamine by the 
monoamine oxidase enzymes in the brain produces too much H2O2. An initial good response 
to symptomatic pharmacological treatment declines with time, and severe side effects 
develop and later on surgical interventions are to be used. The progressive neurodegeneration 
in PD is not arrested by the currently used drug therapies. Hence, recent researches are 
focusing on finding therapies, preferentially herbal drugs.
[25]
 
 
ROTENONE induced PDs 
                   PD can be induced with mitochondrial complex I inhibitors such as the 
environmental toxins rotenone. Rotenone, a commonly used natural pesticide prepared from 
the roots of tropical plants, such as Derris elliptica, can freely cross cell and mitochondrial 
membranes. In vitro, rotenone has been shown to promote the accumulation and aggregation 
of alpha-synuclein and ubiquitin, cause oxidative damage, and endoplasmic reticulum stress, 
and lead to cell death. In vivo, chronic exposure of rats to rotenone induces PD-like 
symptoms, including dopaminergic neurodegeneration and the occurrence of cytoplasmic 
inclusions similar to Lewy bodies. Re- cent studies show that chronic exposure of Drosophila 
to rotenone recapitulates key features of Parkinsonism, including selective loss of 
dopaminergic neurons and locomotor deficits. Although there are also study showing 
contradictory results, most of the evidences are consistent and suggesting that rotenone 
exposure contributes to PD-like symptom and that rotenone-based Parkinson’s disease 
models can be used to test potential compounds for PD intervention.
[26]
 
 
1.1.5 PURPOSE OF THE STUDY 
                     Traditional medicine practitioners have described the therapeutic efficacies of 
many traditional and indigenous plants against diseases.  A large number of plants are used 
by folklore traditions in India for a treatment of parkinsonism. Various research data revealed 
that plants may work as anti-parkinson by multiple mechanisms. There are several reports 
stating that the extracts of several plants, used for parkinson therapy. Natural products that 
are safe, and possess physiological properties are excellent sources of new therapeutics for 
the treatment of parkinson. Some researchers, therefore, have shifted their focus to the 
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potential anti-parkinson properties of plants. Thereby, the search for new agents is ongoing 
and natural products become a great target. Various literature and studies show that the active 
principles triterpenoids, iridoids , and flavonoids are having a crucial role in anti-parkinson 
treatment. Barleria prionitis is rich in these types of triterpenoids, Iridoids, and Flavonoids. 
The purpose of this study is to investigate and evaluate anti-parkinson activity on MPTP and 
Rotenone-induced model by using aqueous extracts of Barleria prionitis. 
1.1.6 HYPOTHESIS 
                       I hypothesize that the presence of active constituents like triterpenoids, iridoids 
and flavonoids in this plant Barleria prionitis after isolation and extraction  may produce 
anti-parkinson activity. To test whether the plant producing the anti-parkinson activity, 
MPTP and Rotenone induced model are selected. The result of these studies will have a 
translational value to anti-parkinson activity. 
1.1.7 SPECIFIC AIMS 
1. To determine the in-vivo anti-oxidant capacity of aqueous extract of Barleria prionitis. 
2. To determine the In-vivo neurotransmitters of aqueous extract of Barleria prionitis. 
3. To employ the aqueous extract of Barleria prionitis  having anti-parkinson activity 
determine by MPTP and Rotenone induced Parkinson model in SD tats and swiss albino 
mice. 
1.1.8 PLAN OF WORK 
1. Literature collection 
2. Selection, collection and authentication of plant materials 
3. Extraction of plant with water by maceration method 
4. Preliminary phytochemical analysis 
5. Pharmacological study 
  Screening of anti-parkinsonian activity using various behavioural paradigms 
 Rota rod 
 Actophotometer 
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 Forced swim test 
 Tail suspension test 
 Hole board test 
  In vivo activity 
a) Estimation of total protein 
b) Antioxidant assays 
 Non-enzymatic antioxidant (GSH) 
 Estimation of Lipid peroxidation (LPO) 
c) Neurotransmitters estimation 
 Dopamine, GABA, Serotonin 
6. Histopathological study  
7. Statistical analysis 
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2. REVIEW OF LITERATURE 
2.1. PARKINSON’S DISEASE 
Parkinson’s disease (PD) is a chronic, progressive neurologic disease. Affecting one in every 
100 persons above the age of 65 years, it is the second most common neurodegenerative 
disease after Alzheimer’s disease. It presents mainly four cardinal motor manifestations such 
as tremor at resr, rigidity, bradykinesia or slowing of movement and postural instability. The 
pathological hallmarks of PD are the presence of intracytoplasmic inclusions from protein 
aggregates called Lewy Bodies (LBs) and the depletion of pigmented dopamine containing 
neurons in the region known as substantia nigra pars compacta. PD is characterized by the 
loss of 50-70% of dopaminergic neurons located in the substantia nigra. Thus far, both the 
cause and the mechanisms of PD remain unknown.
[27,28,30]
 
In about 95% of PD cases there is no apparent genetic linkage which is referred to as sporadic 
PD, but in remaining cases the disease is inherited. Current evidence suggests an involvement 
of both environmental and genetic factors in the progression of PD. Researchers on the 
pathogenesis of PD advanced with the development of animal models. These models have 
been based on the systemic or local administration of neurotoxins that are able to reproduce 
pathological and behavioural changes with PD in mammals. Levodopa  treatment still 
remains as the gold standard for PD therapies. Unfortunately, long term use of L-dopa results 
in dyskinesias (involuntary movements). Current pharmacological therapies are symptomatic; 
none or retard dopaminergic neuron degeneration. Thus the development of animal models is 
essential for better understanding of the pathogenesis and progression of PD and discovering 
therapeutics to treat PD.
[29,31]
 
2.2. DEFINITION  
Parkinsonism is a clinical syndrome characterized by It is characterized by loss of 
dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc).
[29]
 
                                                                                                                                                       
2.3. SIGNS AND SYMPTOMS 
Parkinson’s disease affects movements (motor symptoms). Typically other symptoms include 
disorders of mood, behavioural, thinking and sensation (non-motor symptoms). 
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2.3.1. Motor manifestations 
Tremor: maximal when the limps are at rest, and decreased with voluntary movement.  
Rigidity: stiffness or resistance to passive movement by limbs.                                    
Bradykinesia: slowness and paucity of movement.                                                           
Postural instability: Failure of postural reflexes, which leads to impaired balance and falls. 
Other motor symptoms include: 
Gait freezing: motor block; freezing occurs as a sudden inability to step forward while 
walking. It is transient, last for seconds or minutes, and suddenly abates.                      
Dystonia: abnormal, sustained, painful twisting muscle contraction, often affecting the foot 
and ankle (mainly toe flexion and foot inversion).                                                  
Hypotphonia: soft speech; speech quality tents  to be soft, hoarse, and monotonous.  
Dysphagia: impaired ability to swallow; can lead to aspiration, pneumonia.                    
Masked faces ( a mask like face, also called hypomania), with infrequent blinking.  
Micrographia (small, cramped handwriting)                                                                       
Impaired fine motor dexterity and motor coordination.
[32,33,36]
 
2.3.2. Cognitive and psychiatric manifestitations 
Dementia: slowing of thought and progressing to difficulties with abstract thought, memory 
and behavioural regulation.                                                                                           
Depression:  about 47% of PD patients show evidence of depression.                                   
Short term memory loss.  
Hallucination, delusions, irritability, apathy and anxiety.
[36] 
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2.4. DIFFERENTIAL DIAGOSIS OF PD 
[37]
 
 
Diagnosis 
 
 
Historical features 
 
 
Signs/symptoms 
 
Radiographic finding 
 
Idiopathic 
Parkinson’s 
disease 
 
Difficulty with 
tasks, rigidity, 
tremor 
 
Tremor, rigidity, 
bradykinesia, loss of 
balance, micrographia 
 
No specific CT or 
MRI findings 
 
Drug induced 
parkinsonism 
 
Previous use of 
antipsychotics, 
reserpine, 
metaclopramide 
 
Tremor, rigidity, 
bradykinesia, often 
bilateral symptoms 
 
Normal 
 
Vascular 
parkinsonism 
 
Stepwise 
progression; CVA 
or TIA, co morbid 
cardiovascular 
disease 
 
Fixed deficits from 
previous events 
 
Lesions in white 
matter with or 
without basal 
ganglia 
 
Essential 
tremor 
 
History in 
multiple family 
members, little 
evolution 
 
Tremor often bilateral, 
mild rigidity; no extra 
pyramidal symptoms; 
no response to L-dopa 
 
SPECT shows 
normal 
dopaminergic 
system 
 
Progressive 
supranuclear 
palsy 
 
Onset after 
40 years of age; 
frequent falls 
 
Vertical gaze 
paralysis, postural 
instability, resting 
tremor, dystonia, 
normal olfaction 
 
MRI shows 
mesencephalon 
brain stem 
atrophy involving 
the superior 
colliculi 
 
Table 1 : Differential diagnosis of PD 
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2.5. NEUROPATHOLOGY OF PD 
Parkinsonism is a progressive motor disease that affects 1.5 million Americans. It is the 
second most common neurodegenerative disease after Alzheimer’s and PD affects close to 
5% of the population that are over 65 years old. The degeneration of dopaminergic neurons in 
the substantia nigra lead to PD. Due to abnormal protein folding and ER stress, a toxic 
protein named Lewy bodies are formed that are commonly observed in PD patients. This 
toxic protein, Lewy bodies, is made of different proteins such as α-synuclein, synphilin-1, 
and ubiquitin.  
Lewy bodies have also been observed in other areas of the brain such as hind brain, spinal 
cord and enteric nervous system. Lewy bodies first appear in the periphery, subsequently it 
travels to brain stem and eventually in the cortex. Although there is some controversy as to 
whether all PD patients do have α-synucleinopathy, all α-synucleinopathies have one thing 
common and that is pathology found in discrete location and clinical manifestations may be 
due prionopathy that arose from different regions of the brain. Thus, a misfolded _-synuclein 
can trigger a downstream cascade of events that may lead to clinical symptoms.  
There are other forms of PD that involve abnormally phosphorylated tau such as progressive 
supra nuclear palsy, cortico-basal degeneration, parkinsonism-dementia complex, and fronto-
temporal dementia with Parkinsonism.
[28,29] 
 
 
 
Figure 1: Neuropathology of PD 
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A. Normal nigrostriatal pathway (in red)- It is composed of dopaminergic neurons whose cell 
bodies are located in SNpc .These neurons project (thick solid red lines) to the basal ganglia 
and synapse in the striatum (i.e. putamen and caudate nucleus). The photograph demonstrates 
the normal pigmentation of the SNpc, produced by neuromelanin within the dopaminergic 
neurons. 
B. Diseased nigrostriatal pathway (in red)- In PD, there is a marked loss of dopaminergic 
neurons that project to the putamen (dashed line) and a modest loss of those project to the 
caudate (thin red solid line). The photograph demonstrates depigmentation (i.e., loss of dark 
brown pigmentation neuromelanin) of SNpc due to the marked loss of dopaminergic neurons.  
C. Immunohistochemical labelling of lewy bodies in SNpc dopaminergic neuron. 
Immunostaining with an antibody against α-synuclein reveals a LB (black arrow) with an 
intensely immunoreactive central zone surrounded by a faintly immunoreactive peripheral 
zone (left photograph). Immunostaining with an antibody against ubiquitin yields more 
diffuse immunoreactivity within LB (right photograph).
[29] 
 
2.6. EPIDEMIOLOGY OF PD 
PD is the most common neurodegenerative disorder of mid to late life in developed nations. 
During final decades of last century, in U.S. and Western Europe, 1 in 200 persons aged  
around 60-69 had PD. For people in their 70’s this increased  to 1 in 100 persons and for the 
people in their 80’s in every 35 persons had PD. In developing countries like China in the 
1980’s only 1 in 1000 persons in their 60’s was expected to have PD, but recent studies states 
that the prevalence is similar to that in U.S. 
In among the five most populous nations, estimate of the number of individuals with PD over 
age the 50 was found to between 4.1 and 4.6 million in 2005 and 6.2 in 2015. This is 
expected to 8.2 million , by the year 2030.
[38] 
 
Population of elderly Indians has increased from 5.6% (51 million)  in 1961 to 7.1%  ( 71 
million) in 2001. This increasing life expectancy of Indians, in the last decade, is likely to 
result in an age related disease like PD and Alzheimer  disease. 355 million (61%) elderly 
people out of 580 million lives in developing countries, and of these 77 million (22% of total) 
lives in India. It was estimated that 33 million Indians do have neurological disorder. It was 
found that, the prevalence of PD was more in rural (41/105) than urban (14/105) population 
and was commoner among men. 
[39]
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2.7.  RISK FACTORS OF PD 
2.7.1. Environmental factors 
1-methyl-4-phenyl,2,3,6-tetra hydropyridine (MPTP)
[30]
  
MPTP is a by-product of the chemical synthesis of narcotic meperidine analogue. It is highly 
lipophilic; easily crosses the BBB and converts to 1-methyl-4-phenyl-2,3-dihydropyridinum 
ion (MPTP+) via monoamine oxidase B within non dopaminergic cells and then to MPP+. 
MPP+ is transported to dopaminergic neurons by DAT and therefore exhibits selective 
toxicity to dopaminergic neurons. People intoxicated with MPTP develop a syndrome 
identical to PD.  
Pesticides
[31] 
 
Human epidemiological studies have implicated residence in a rural environment and related 
exposure to herbicides and pesticides with an elevated risk of PD. Paraquat is a member of 
chemical class bipyridyl derivatives, has been used as herbicide. It is structurally similar to 
MPP+. Exposure to a combination of paraquat and maneb, which is also a pesticide, 
exacerbates dopaminergic degeneration in the rodent model and cause higher incidence of PD 
in humans. Rotenone, which is used as an insecticide is a potent inhibitor of complex I. it 
disrupts mitochondrial function and plays important roles in nigral cell degeneration in PD.  
Caffeine, cigarette
[40]
  
Cigarette smokers had 60% lower risk for the development of PD than people without a 
history of smoking. Several studies revealed that cigarette smoking inhibits monoamine 
oxidase activity and nicotine stimulates dopamine release. Thus it suppresses free radical 
generation and protects against dopaminergic cell death. Similarly coffee drinking could 
result in a 30% decreased risk of PD compared with non coffee drinkers. Caffeine had similar 
effects as A2A antagonist.  
Disease process and dual hit theory
[40]
  
Neuronal degeneration in PD may extend from peripheral systems, such as olfactory and 
autonomic systems to cortices. Dual hit hypothesis suggests that neurotropic pathogens may 
enter the nervous systems via both nasal and intestinal epithelium and this may promote α-
synuclein aggregation. 
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2.7.2.  Genetic factors 
Synuclein 
α-synuclein is a 140 aminoacid protein that is abundantly expressed throughout the brain, and 
especially in presynaptic nerve terminals. Two missense mutations [ Ala53           Thr            
(A53T) and Ala30           Pro (A30P)] in α-synuclein cause dominantly inherited PD. In 
straiatal dopaminergic terminals, α-synuclein participates in the modulation of synaptic 
functions. α-synuclein is abundant in LBs. it’s misfolding and formation of amyloid fibrils 
may be responsible for the neurotoxicity. Aggregation of α-synuclein is thought to be a key 
event in dopaminergic neuronal cell death in sporadic PD.
[32]
 
Parkin 
Parkin, a 465 amino acid  protein, contains two RING finger domains separated by an in-
between RING (IBR) finger domain at the c terminus and an ubiquitin-like homology domain 
at the N terminus. Parkin is an E3 ubiquitin ligase, a component of ubiquitin-proteasome 
system that identifies and targets misfolded proteins to the proteasome for degeneration. 
Heterozygote mutations in parkin may lead to dopaminergic dysfunction and later onset of 
PD. 
[40]
 
Ubiquitin C-Terminus Hydrolase-L1 
A dominant mutation (193M) in UCH-L1 was identified in one family with inherited PD, 
where as polymorphism (S18Y) of  UCH-L1 appears to be protective for the development of 
PD. UCH-L1 ligase activity is decreased by the pathogenic 193M mutation and increased by 
the protective S18Y polymorphism.
[40]
 
DJ-1 
DJ-1 appears to protect cells against mitochondrial complex-1 inhibitors and oxidative stress 
induced by hydrogen peroxide. This effect is abrogated by DJ-1 mutations or by DJ-1 
knockdown  using SiRNA. DJ-1 can act as an antioxidant.
[29]
  
PINK 1 gene 
Missense and truncating mutations in PINK 1 gene found to cause autosomal recessive PD. 
PINK 1 protein consists of a kinase domain and a mitochondrial targeting motif. Its 
neuroprotective  property os lost by G309D mutation which is seen in certain families.
[40]
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LRRK2 
LRRK2 mutations were identified as the causative gene for PARK8- linked familial PD. 
R1628P and G2385R are polymorphic mutations and have been demonstrated as risk factors 
for sporadic PD in Asian populations. An LRRK2 mutation causes neuronal loss in substantia 
nigra accompanied by LBs.
[41]
 
 
2.8.  PATHOGENESIS OF PD 
 
Figure 2: Mechanism of neurodegeneration 
2.8.1.  Misfolding and aggregation of proteins 
Accumulation of misfolded proteins is a key event in PD neurodegeneration. Protein 
aggregates could directly cause damage or by deforming the cell or by interfering with 
intracellular trafficking in neurons. Pathogenic mutations may directly induce abnormal 
protein conformations (α-sunuclein) or damage the ability of the cellular machinery to detect 
and degrade misfolded proteins (Parkin, UCH-L1). Oxidative damage, linked to 
mitochondrial dysfunction and abnormal dopamine metabolism, may also promote misfolded 
protein conformations.
[29,32]
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2.8.2.  Mitochondrial dysfunction and oxidative stress 
Oxidative phosphorylation defect play a role in the pathogenesis of PD. This is supported by 
finding that MPTP blocks the mitochondrial electron transport chain by inhibiting complex I. 
In vitro studies indicate that complex I defect may subject cells to oxidative stress and energy 
failure. Inhibition of complex I increases the production of the ROS superoxide. 
Increased reactive oxygen species (ROS) production from dopamine metabolism or 
dysfunctional mitochondria may induce cellular damage and death through modification of 
nucleic acids, proteins and lipids. Age related depletion of glutathione levels precipitates the 
accumulation of oxidizing free radicals such as hydrogen peroxide, hydroxyl ions and 
superoxide in the brain. 
Dopamine produced by nigral neuron leads to both mitochondrial dysfunction and impaired 
proteolysis. Metabolism of DA produces hydrogen peroxide and superoxide radicals and 
auto-oxidation of DA produces DA-quinone, a molecule that damage protein or further 
converted to neuromelanin. The modification of bio molecule by hydroxyl radicals or 
dopamine quinine exerts toxic effect on dopaminergic neurons.
[41,42]
 
2.8.3.  Programmed cell death 
Activation of programmed cell death machinery believed to be a factor that triggers the death 
of dopaminergic neurons in PD. In PD, SNpc dopaminergic neurons with increased 
expression of anti-PCD protein Bcl-xl and activated PCD effector protease caspase 3 have 
been found. Other molecular markers of PCD altered included activation of caspase-8 and 
caspase-9. 
[32]
 
                                              MAO-B 
                          Dopamine                             DOPAC + H2O2 + NH3 
  Auto oxidation                                                                                  
 5-s-cysteinyl dopamine derivatives 
O2 
-
, H2O2 Dopamine quinone  
 Neuromelanin 
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2.9.  ANIMAL MODELS OF PD 
Systemic administration 
 
MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)                                                                            
PARAQUAT                                                                                                                                          
ROTENONE 
 
Local administration                                                                                                                                               
6-HYDROXY  DOPAMINE                                                                                        
LIPOPOLYSACCHARIDE     
 
2.9.1.  MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)  
1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP), is a potent neurotoxin & highly 
lipophilic. After systemic administration it rapidly crosses the blood-brain barrier, enters 
astrocytes and is metabolized to its active metabolite MPP+ by monoamine oxidase-B 
(MAO-B). MPP+ is able to inhibit complex 1 of the mitochondrial electron transport chain, 
resulting in the formation of ROS & leading to reduced ATP production. 
Neuroprotection suggests preventing or slowing disease progression. Nevertheless, despite 
advances toward this goal, all current treatments are symptomatic; none halt or retard 
dopaminergic neuron degeneration.
[33]
 
 
2.9.2.   ROTENONE  
PD can be induced with mitochondrial complex I inhibitors such as the environmental toxins 
rotenone. Rotenone, a commonly used natural pesticide prepared from the roots of tropical 
plants, such as Derris elliptica, can freely cross cell and mitochondrial membranes. In vitro, 
rotenone has been shown to promote the accumulation and aggregation of alpha-synuclein 
and ubiquitin, cause oxidative damage, and endoplasmic reticulum stress, and lead to cell 
death. In vivo, chronic exposure of rats to rotenone induces PD-like symptoms, including 
dopaminergic neurodegeneration and the occurrence of cytoplasmic inclusions similar to 
Lewy bodies. Re- cent studies show that chronic exposure of Drosophila to rotenone 
recapitulates key features of Parkinsonism, including selective loss of dopaminergic neurons 
and locomotor deficits. Although there are also study showing contradictory results, most of 
the evidences are consistent and suggesting that rotenone exposure contributes to PD-like 
symptom and that rotenone-based Parkinson’s disease models can be used to test potential 
compounds for PD intervention.
[54] 
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Figure 3: Effects of toxins used in model of Parkinson’s disease on dopamine cells 
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2.10.   DRUG CLASSES FOR PARKINSONISM
[43]
  
 
I.  Drugs affecting brain dopaminergic system 
 Precursors of Dopamine: Levodopa 
 Inhibitors of Dopamine metabolism: 
 COMT inhibitors: Tolcapone, entacapone 
 MAO-B inhibitors: Selegiline,rasagiline  
 Dopamine releasers: Amantadine 
 Dopamine receptor agonists: 
 Ergot derivatives: Bromocriptine, Pramipexole, Ropinirole 
 Non-Ergor derivatives: Lysuride 
II. Drugs that affect brain cholinergic system 
 Central anti-cholinergics: Procyclidine, benzhexol 
 Antihistaminics: Promethazine, orphenadrine 
 
 
Figure 4: Site of action of current therapies 
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2.11.  MANAGEMENT OF PD
[37] 
 
Idiopathic parkinson’s disease 
 
                                      Yes                                                                                      
                                                    No 
                                                                                             
Consider CT/MRI to rule 
out   normal pressure  
hydrocephalus or a 
vascular cause ; consider 
referral to subspecialist 
No functional impairement 
 
Monitor for disease progression 
 
Disease progresses             functional impairement                   consider immediate release                                                                                                  
                                                                                                    carbidopa /levodopa or a                                                                                                                                                                                                  
                                                                                                    dopamine agonist 
 
                            Continued disease progression                 increase dopamine agonists to                                                                                                                                                                                             
                                                                                                    maximum tolerated dose,  
                                                                                                    then  add  carbidopa/levodopa 
 
                            Motor complication develop               carbidopa/levodopa ( 5 times a        
day ); consider adding 
dopamine agonist, MAO-B 
inhibitor or COMT inhibitors 
                                Severe motor fluctuations     consider referral for                                           
apomorphine therapy  
 
             
                                   No improvement  
            
 severe dyskinesia         
                                                                                           Refer for functional                                                                                 
reduce carbidopa/levodopa           no improvement              neurosurgery  
dose; consider amantadines                                                                           
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2.11.1. Limitation of current therapies
[43] 
 
Levodopa  
The gold standard of PD therapy; acts as aprecursor of dopamine. When levodopa is 
administered orally it is rapidly decarboxylated; thus high dose is required for desired effect 
which induces nausea and vomiting in patients. Longterm treatment of levodopa results in 
adverse motor effects which limits its use including on-off phenomenon, wearing off, dose 
failure, akinesia and dyskinesias. 
Selegiline 
This MAO-B inhibitor prevents the in vivo metabolism of dopamine. Its main use is as 
adjuntive therapy with levodopa which may lead to potentiated side effects. Studies suggest 
that selegiline may retard disease progression and delays the need for levodopa. However, 
therapeutic effect is mild when used alone. 
Amantadine 
Amantadine, an antiviral agent was found by chance to be effective in PD. It is effective in 
reducing diskinesias. Its CNS effects include restlessness, depression, confusion and 
hallucinations. 
Anticholinergics 
Trihexyphenidyl or benztropine are specifically effective against tremor. Side effects such as 
confusion, drowsiness, agitation and hallucination are common. Drug withdrawal leads to 
precipitation of acute parkinsonian symptoms. 
Dopamine receptor agonists 
They may be used alone to delay the need for levodopa or used with levodopa to increase 
their effectiveness. The ergot derivatives causes psychiatric disturbances and cardiovascular 
problems that can progress to myocardial infractions. Even at lower doses patients experience 
orthostatic hypotension, constipation, dyskinesias, confusion and insomnia. 
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COMT inhibitors 
COMT inhibitors are used mainly in combination with levodopa. The incidence of sleep 
disturbances, orthostatic hypotension, dyskinesias, confusion and insomnia. Tolcapone 
produce heparotoxicity and has been restricted in many countries.  
 
2.11.2. Newly researched neuroprotective agents 
Nicotine                                                                                                                                      
Nicotine, principle alkaloid in tobacco evokes the release of dopamine from the striatum; thus 
it protects nigrostriatal neurons from degeneration. It acts by the activation of presynaptic 
nicotinic α4, β2 and α7 receptors located on the dopaminergic nerve terminals. It also acts as 
free radical scavenger. 
[44]
 
Anti-inflammatory agents                                                                                                               
The enzyme cyclo-oxygenase (COX) as well as inflammatory mediators like nitric oxide 
were reported to increase in PD. Non-selective COX-inhibitors, aspirin and the COX-2 
inhibitors meloxicam were reported to confer neuroprotection in MPTP induced dopamine 
depletion in mice. Salicylic acid acts as free radical scavengers in the brain, but its 
neuroprotective ability is independent of prostaglandin mediation.
[45]
 
Melatonin                                                                                                                              
Melatonin, a serotonin derivative is a hormone synthesized naturally by neurons in the pineal 
gland. It has antioxidant properties and act as a free radical scavenger. It causes dose-
dependent reduction in the production of dopaminergic neurodegenerating hydroxyl free 
radicals.
[46] 
 
Monoamine oxidase-B (MAO-B) inhibitors                                                                                  
Rasagiline, a noval MAO-B inhibitors potentially reduces the progression of PD. It is 
effective in alleviating symptoms of PD. Youim et al., (2005) devolped a compound, 
Ladostigil which has both ChE and MAO-B inhibitory activity; a potential treatment for PD 
patients with dementia.
[47]  
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Selenium                                                                                                                                    
Selenium, an essential trace metal present in the body has been found to be effective in 
delaying neurodegeneration due to its role in the functioning of the antioxidant enzyme 
glutathione peroxidise (GPx).
[48]
  
Iron-chelators                                                                                                                           
The use of iron chelators including desferoxamine and the newer agent V-28; and 
combination with MAO-B inhibitors, rasagiline yielded reduction in the degeneration and 
formation of protein aggregates. They acts by interfering α-synuclein iron reactivity or by 
reducing iron content in the substantia nigra.
[49] 
 
Vitamin A, C and E                                                                                                                    
Levels of 4-hydroxy-2,3-noneal (HNE), an aldehyde generated during lipid peroxidation and 
8-hydroxyguanosine, a nucleoside oxidation product are increased in substantia nigra of PD 
patients. Vitamins A, C and E are proven antioxidants which prevents lipid peroxidation. 
Treatment with high doses of Vitamin A and C delayed the use of levodopa or DA agonists 
by 2.5 years.
[50] 
 
 
2.11.3. Non-pharmacological treatment 
Gene therapy                                                                                                                          
Genes those encoding tyrosine hydroxylase, guanosine triphosphate cyclohydrolase I and 
aromatic L-amino acid decarboxylase allow for an increase in the production of dopamine. 
The differentiation of these neuron is mediated by agents such as transforming growth factor 
beta (TGF-β) and bone morphogenic factors (BMPs). Thus far, glial cell line-derived 
neurotrophic factors (GDNF) have proven to be the most promising option to restore 
dopaminergic activity in substantia nigra. Proposed systems have ranged from adenoviral and 
lentiviral nigrostriatal implants to liposomes.
[50] 
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Surgical methods 
Prior to the commercial availability of levodopa, treatment for PD emphasized surgical 
intervention. Surgery is considered for people with intolerable adverse side effects from 
medication, and those who have significant cognitive capacity. 
Pallidotomy- destruction of a small portion of the brain that is overactive, by use of an 
electric probe. This primarily reduces dyskinesia; minimal effects on bradykinesia and 
rigidity. 
Thalamotomy- involves the removal of the thalamus in the brain. This procedure is rarely 
performed and considered as safe and effective to treat tremor. 
Thalamic stimulation- involves the insertion of an electrode wire into the thalamus, the other 
end connected to a pulse generator placed under the skin in the thorax; effective in the 
management of tremor in PD. 
Deep brain stimulation- An alternative procedure used to destroy small region in the brain. A 
thin electrode implanted into the brain prevents transmission of impulse for involuntary 
movements.
[51] 
 
2.11.4.  Herbal remedies 
Herbal medicines have been main source of primary health care in all over the world. About 
80% of the world populations are still dependent on traditional medicines. The lack of 
effective and widely applicable pharmacological treatments in the modern therapy for 
neurodegenerative disorders may explain a growing interest in the traditional medicines. In 
Indian medical system Ayurveda, “Kambaveta” is the term used to explain Parkinson’s 
syndrome. In recent years, increasing interest has been devoted to the treatment of PD by 
herbal medicines.
[53,54]
 
Mucuna pruiens; (Family: leguminosae) 
Mucuna pruiens commonly known as velvet bean or the cowhage is used in spasms 
associated with Parkinsonism. Its seeds are well known to contain levodopa and possess 
androgenic, analgesic, anti-inflammatory, antiparkinson’s and  antispasmodic activities MP 
extract shows twice the antiparkinson’s activity compared with synthetic levodopa in animal 
models.
[53] 
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Acanthopanax senticocus Harms; (Family: Alariaceae) 
Ethanol extract of Acanthopanax senticocus stem bark at dose of 250mg/kg shows 
prophylactic effect on behavioural dysfunction of parkinsonism such as bradykinesia, 
catalepsy, depression by significant increase in the dopamine level in the striatum in MPTP 
models.
[54]
  
Ginko biloba; (Family: Ginkgoaceae) 
The neuroprotective effects of a standardised extract of Ginko biloba were investigated on 6-
OHDA induced neurotoxicity in rat. The pre-treatment EGb for 3 weeks cause significant 
restoration of striatal dopamine and its metabolites, it is a potent inhibitors of MAO-B. The 
loco motor deflects were restored and causes increase in the content of GSH.
[52] 
 
Withani somnifera; (Family: Solanaceae) 
Withani somnifera have significant role in prevention of various CNS disorders, particularly 
in epilepsy, stress and neurodegenerative disease such as Parkinson’s and Alzeimer’s disease. 
The root extract at dose of 100mg/kg shows significant improvement in motor neuron 
function, catecholamines and antioxidant level; prevent lipid peroxidation.
[52] 
 
Hypericum perforatum; (Family: Hypericaceae) 
Pre treatment with standardised extract Hypericum perforatum for 45 days in rotenone 
exposed rats, exerts an antioxidant action which was related with decrease of MnSOD 
activity, increase SOD and CAT activity and protect the cells from damaging effect of H202; 
shows neuroprotective activity.
[53] 
 
2.12. Barleria Prionitis linn 
 Piush Sharma, et al; (2013) investigated and reported the phytochemical and ethanomedical 
values of Barleria prionitis L.(Acanthaceae) which have been established against various 
disease models using modern scientific methodologies and tools. They concluded that 
Barleria prionitis is abundant in terms of presence of phytoconstituents and their active 
secondary metabolite. The reported pharmacological activity include anti-fertility activity, 
anti-oxidant activity, anti-inflammatory, hepatoprotective, anti-diabetic activity, anti-dental 
decay activity and anti-microbial activity.
[54]
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 Nidhi et al., (2013) evaluated the antibacterial activity of rhizome of Barleria prionitis in 
methanol extract. The antibacterial potential was measured by agar disc plate method. The 
methanol extract showed antibacterial activity against two Gram’s positive and two Gram’s 
negative bacteria. By using Gas chromatograpy with mass spectrophotometric detector the 
active phytocomponents of Barleria prionitis were revealed and 27 constituents identified. 
All the results supported that the extract can be used to prevention of bacterial infection.
[55]
  
Manider Karan et al., (2013) assessed topical anti-inflammatory activity of Barleria 
prionitis and Barleria Cristata against croton oil induced ear oedema in female rats. Different 
extract using methanol, hexane, chloroform, ethyl acetate, butanol and aqueous extract of 
each Barleria species were evaluated at a dose of 200-400 mg/ml prepared in croton oil 
solution. From the above study they concluded that chloroform extract of  Barleria prionitis 
showed best topical activity with 88.31% inhibition of ear oedema..
[56]
  
 Kuldeep Singh et al., (2013) evaluated the anti-inflammatory effect of methanol extract of 
Barleria prionitis on carragennan induced rat paw oedema. They concluded that methanolic 
extract of Barleria prionitis for the dose of 500 mg/kg p.o shown anti-inflammatory activity 
in the early stage as well as in the late stage of the study. The inhibition of Carragennan 
induced paw oedema by crude extract is due to inhibitory activity of lipoxygenase 
enzymes.
[57]
 
 Manjusha et al., (2013) evaluated the gastro protective activity of methanolic extract of 
Barleria prionitis on ethanol and indomethacin induced ulcer models in rats. Parameters like 
volume of gastric juice, pH, free acidity, total acidity, AST and ALT were determined. The 
reduction in ulcer index in Barleria prionitis treated animal was found to be statistically 
significant when compared with control groups in both the model. They concluded that the 
methanolic extract of Barleria prionitis  possess antiulcer activity, which supports the 
traditional use of this plant in treating gastric ulcer.
[58]
 
Swathi Paul. et al., (2012) reported the potent antibacterial activity of different leaf extracts 
of Barleria proinitis L. They studied the antibacterial effect and the minimum inhibitory 
concentration (MIC) using different extract (petroleum ether, chloroform, ethanol (70%)) and 
column fraction of Barleria prionitis leaf. S. Typhi, V. Cholera, M. Lute, L. sporogenus and 
Citrobacter were inhibited at 5mg/ml level. B. subtils inhibited at 3.33 mg/ml level. B. cereus 
and Providencia were inhibited at 50 mg/ml.
[59]
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Reema Dheer et al., (2011) studied the antibiotic activity of alcoholic extract of leaf and root 
of Barleria prionitis in normal and alloxan induced diabetic rats. The alcoholic extracts of 
leaves and alcoholic extracts of roots of Barleria prionitis were given at a dose of 200 mg/kg 
for 14 days. They concluded from the study that animals treated with the alcoholic extract of 
leaves of Barleria prionitis significantly decreased the blood glucose level and glycosylated 
haemoglobin and an increase in serum insulin level and liver glycogen, where as decrease in 
weight was arrested. The alcoholic root extract showed a non significant antidiabetic activity 
in experimental animals.
[60]
 
 Chavan Chetan et al., (2011) investigated the antioxidant activity of ethanolic and aqueous 
extract of whole plant of Barleria prionitis. The study indicated that the ethanol and aqueous 
extract of Barleria prionitis possesses significant antioxidant activity. The order of 
antioxidant potency of the whole plant extract is ethanol > aqueous. The phenolic content of 
was determined using Folinciocalteau reagent. They concluded that the presence of high 
levels of phenolic compounds in the ethanolic extract contributed to the observed antioxidant 
activity.
[61]
  
 R.M.Santiago et al., (2010) reported the depressive like behaviour and neurotransmitter 
alterations in PD models induced by intranigral injection of MPTP, 6-OHDA and rotenone. 
The data indicate that MPTP, 6-OHDA and rotenone were able to produce anhedonia and 
behavioural despair. These altered behavioural responses were accompanied by reductions of 
striatal DA, homovanillic acid (HVA) and DOPAC restricted to the 6-OHDA group. 
Additionally, decreases on the hippocampal serotonin (5-HT) content were detected for the 
MPTP, 6-OHDA and rotenone groups.
[62] 
 Ramya kubar B et al., (2011) evaluated the neuroprotective effect of various extracts of 
Prosopis chilenis (PC) seeds in MPTP mouse models. PC seed extract was administered at 
different doses in different groups once a day for seven days and the first dose was given 30 
min prior to first MPTP injection (20mg/kg/i.p; 4 injections at 2h intervals).The alcoholic 
extract at given doses [100,200 and 300mg/kg (p.o)] significantly dose dependently increased 
the spontaneous motor activity, grip strength and alertness. Alcohol, ethyl acetate and 
aqueous extract of PC significantly improved the brain dopamine, nor epinephrine, 
epinephrine and 5-HT at a dose of 200 and 300mg/kg. These results indicate that PC extracts 
had neuroprotective effect on MPTP induced PD.
[63]
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2.13. PLANT PROFILE
[64-67] 
BARLERIA PRIONITIS 
Plant name      :  Barleria prionitis also known as porcupine flower. 
Family             :  Acanthaceae 
Vernacular Names 
Hindi               :  Vajradanti 
Sanskrit           :  Karunta 
English            :  Common Yellow Nail Dye Plant 
Bengali            :  Kantajati 
Tamil               :  Shemuli 
Malayalam       : Manjakanakambaram 
Morphological characters: 
Barleria prionitis is a branched annual shrub of about 1-3 feet height with flower and is a 
spiny invader. The spines in leaf axils are 5-20mm long. Flowers are yellow or whitish in 
color, 3-4cm long and broad, tubular, sessile in leaf axils. The white flower variety is bitter in 
taste. The stem is generally single, but may have multiple stems or branches near the ground. 
The stem branches are stiff, round, light gray colored and globrous. The roots are tap like and 
with lateral system. The leaves are elliptic to oblong, up to 3-10 cm long and 15.4 cm broad. 
The seeds of  Barleria prionitis are compressed, about 8mm length and 5mm width. The seeds 
are flattened and covered with matted hairs. The fruits are ovoid and capsule shaped. 
Geographic distribution 
The Barleria prionitis is native to tropical areas of east Africa and Asia, also found 
throughout tropical Asia such as India and Srilanka and in south Africa also. 
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Ecology 
Porcupine flower or Barleria prionitis grows in a wide variety of well drained soils derived 
from igneous, metamorphic, and sedimentary rocks. It grows in areas receiving from about 
750 to 900 mm of mean annual precipitation. Porcupine flower is found throughout the hotter 
parts of India and defoliates annually during the dry season. The species is moderately 
intolerant of shade, growing in both full sunlight and under light forest canopies. 
Growth and Management  
The plant Barleria prionitis flower from September to December and fruit from January to 
April. Forty-four percent of the seeds sown on commercial potting mix germinated between 
13 and 77 days following the sowing. Matured plants add up to 0.5 m / year to their height 
and nursery seeding reach 0.6 m in 6 months. The shrub lives about 4 years. 
Chemical constituents 
Barleria prionitis consist of acabarlerin, barlerin, β- sitosterol, flavanol, glycoside, iridoids 
and scutellarein-7-neohesperidoside. 
Aerial parts of Barleria prionitis consist of phenyl ethanol glycoside ,barlerinoside along 
with six iridoid glycosides, shanzhiside methyl ester, 6-o-trans-p-coumaroyl-8-o-acetyl 
shanzhiside methyl ester, barlerin, acetyl barlerin, 7-methoxy diderroside, luplinoside. Also 
prinoside A, prinoside B, prinoside C. 
Traditional uses 
Traditionally the plant is used for asthma, whooping cough and the leaves and roots are used 
against toothache, rheumatism, cataract, leucoderma, scabies, liver ailments, piles treatment, 
diuretic, ulcers and also in cut, wounds, malaria, fever and irritation control. 
Pharmacological activity 
Anti-fertility activity, anti-oxidant activity, anti-inflammatory activity, hepatoprotective  
activity, anti-microbial activity, anthelmintic, anti dental decay activity, anti-diabetic activity, 
anti-diarrhoeal activity, diuretic activity, besides these it has got AChE inhibitory activity, 
anxiolytics. 
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Figure 5: Barleria Prionitis linn 
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3. METHODOLOGY 
3.1 COLLECTION AND AUTHENTICATION OF PLANT 
The whole plant of Barleria prionitiswere collected from the surrounding areas of 
Erode district, Tamilnadu, India during the month of Decemberand authenticated by 
Botanical survey of India (BSI) southern circle, Coimbatore, Tamilnadu. The authentication 
certificate number is No.BSI/SRC/5/23/2016-14/TECH/2108. Soon after collection the aerial 
parts were cleaned, driened in shade and crushed to a coarse powder, stored in an air tight 
plastic container, until further use. 
3.2 EXTRACTION OF PLANT MATERIAL 
            Coarsely powdered whole plant of Barleria prionitis were extracted with water for 48 
hours at room temperature. After extraction the extracts were evaporated by using rotary 
evaporator and dried at room temperature. The obtained crude extracts were weighed and 
stored at 4
ᵒ
C for the further analysis. 
3.3. QUALITATIVE PHYTOCHEMICAL ANALYSIS OF AEBP 
[68-71] 
 preparation of sample
 
            A small quantity of extract was dissolved in 5ml of distilled water and then filtered. 
The filtrate was tested to detect the presence of different phytochemical constituents in the 
sample. 
3.3.1. DETECTION OF CARBOHYDRATE: 
 Small quantity of extract was dissolved in 4ml of distilled water and filtered. The 
filtrate was collected and subjected for the following tests. 
a. Molisch’s test: 
 1 ml of filtrate was treated with 2-3drops of 1% alcoholic α-napthol solution and 2 ml of 
conc. sulphuric acid was added along the sides of the test tube. Appearance of brown to violet 
ring, indicate the presence of carbohydrate. 
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b. Fehling’s test:  
 To the Fehling solution A and B extract was added and boiled. The formation of brick 
red precipitate indicates the presence of reducing sugar. 
c. Benedict’s test: 
            1 ml of extract was added to 5ml of Benedict’s reagent, was added and boiled for 2 
mins and cool. Formation of a red precipitate shows the presence of sugars. 
3.3.2. TEST FOR GLYCOSIDES: 
a.Legal’s test:           
            The filtrate was hydrolyzed with dilute hydrochloric acid and heated on water bath.                                
Then added 1ml of pyridine and few drops of sodium nitroprusside solution, made alkaline 
with sodium hydroxide solution. Appearance of pink to red colour shows the presence of 
glycosides. 
b.Baljet test: 
           1ml of extract was added to 1ml of sodium picrate solution and the yellow to orange 
colour shows the presence of glycosides. 
c.Keller killiani test: 
           To 2ml of extract, add glacial acetic acid, trace quantity of ferric chloride and add 2 to 
3 drops of concentrated sulphuric acid. reddish brown colour appears at the junction of two 
liquid indicates the presence of cardiac glycosides. 
3.3.3. DETECTION OF ALKALOIDS: 
 Small quantity of extract was treated with few drops of dilute hydrochloric acid and 
filtered it. The filtrate was collected and subjected for tests with following reagents.                                                                                                                                                                                                                                                                                                                                        
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a. Mayer’s reagent: 
 To the filtrate potassium mercuric iodide was added. The formation of cream colour 
precipitate, it shows the presence of alkaloids.  
b. Dragendroff’s reagent:         
            To the filtrate potassium bismuth iodide was added. If it shows reddish brown 
precipitate, indicates the presence of alkaloids. 
c. Wagner’s reagent:  
 To the filtrate iodine in potassium iodide solution was added. If it shows reddish 
brown precipitate, indicates the presence of alkaloids. 
d. Hager’s reagent:  
 To the filtrate saturated aqueous solution of picric acid was added. Formation of 
yellow precipitate indicates the presence of alkaloids. 
3.3.4. DETECTION OF PHYTOSTEROL AND STEROIDS: 
 Small quantity of extract was dissolved in 5ml of chloroform and then subjected to the 
following tests.         
a. Salkowski test:  
 To the above solution 1 ml chloroform and few drops of concentrated sulphuric acid 
was added. The test tube was shaken for few minutes. The development of red colour in 
chloroform layer indicates the presence of steroids. 
b. Liebermann- Burchard reaction:       
 To the above solution 1 ml of chloroform and few drops of                                                            
concentrated sulphuric acid and 1-2 ml of acetic anhydride were added. Development of red 
colour first, then blue and finally green colour, indicates the presence of steroids. 
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3.3.5. DETECTION OF PROTEINS AND AMINOACIDS 
 Small quantity of the extract was dissolved in few ml of water and filtered. The 
collected filtrate was used for following tests. 
a. Biuret test: 
 Filtrate was treated with 5% sodium hydroxide and few drops of 1% copper sulphate 
solution. Formation of violet or pink colour indicates the presence of proteins. 
b. Ninhydrin test: 
             To the filtrate Ninhydrin reagent was added. Development of violet or purple colour 
indicates the presence of amino acids. 
3.3.6. DETECTION OF TANNINS: 
a. Lead acetate test:  
  To 5 ml of aqueous extract was treated with 1 ml of 10% lead acetate solution.  
Yellow colour precipitation, indicates the presence of tannins. 
b.Vanillin hydrochloride test: 
           1ml of extract was added with vanillin hydrochloride. Formation of purplish red colour 
indicates the presence of tannins. 
3.3.7. DETECTION OF FLAVONOIDS 
a. Zinc hydrochloride reduction test: 
            Treat extract with mixture of zinc dust and concentrated hydrochloric acid. Formation 
of red colour indicates the presence of flavonoids. 
 
 
Methodology 
 
Department of Pharmacology, KMCH College of Pharmacy  36 
 
b. Alkaline reagent test: 
           To the extract, add few drops of sodium hydroxide solution. Formation of an intense 
yellow colour, which turns to colourless on addition of few drops of dilute hydrochloric acid, 
indicates the presence of flavonoids. 
3.3.8. DETECTION OF SAPONINS 
a. Foam test: 
 The extract was diluted with distilled water to 20 ml and shaken in a graduated 
cylinder for 15 minutes. Development of stable foam suggests the presence of saponins. 
b. Froth test: 
            To 5 ml of test sample add few drops of sodium bicarbonate. Shake the mixture 
vigorously and keep it for 3 minutes. A honey comb like froth formation indicates the 
presence of saponins. 
3.3.9. DETECTION OF TRITERPENOIDS 
a. Libermann-Burchard test: 
 To the extract add few drops of acetic anhydride, followed by few drops of 
concentrated sulphuric acid. A brown ring forms at the junction of two layers and the upper 
layer turn green colour, infers the presence of phytosterols and formation of deep red colour 
indicates the presence of triterpenoids. 
b.Salkowski Test: 
5ml of extract was mixed in 2ml of chloroform and concentrated sulphuric acid was 
carefully added to form a layer. Formation of reddish brown coloration of the interface 
indicates the presence of triterpenoids. 
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3.3.10. TEST FOR PHENOLS: 
a.Ferric chloride test: 
              To 1 ml of extract, add 2 ml of distilled water followed by few drops of 10% ferric 
chloride. Formation of blue or green colour indicates the presence of phenols. 
b. Lead acetate test: 
             Dilute 1 ml of extract with 5 ml of distilled water and to this add few drops of 1% 
lead acetate solution. Formation of yellow colour precipitate indicates the presence of 
phenols. 
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3.4. EVALUATION OF ANTI-PARKINSON STUDY OF AQUEOUS 
EXTRACT OF Barleria prionitis linn 
Table 2: Selection of animal for MPTP induced Parkinson evaluation 
Species Swiss albino mice 
Age 3 month 
Body weight 25-30 g 
Gender Male 
No: of animals 30 
 
Male Swiss albino mice 3 month of age, and 25-30 g body weight were offered by KMCH 
College of Pharmacy, Coimbatore. All the rats were kept at room temperature and allowed 
to acclimate in standard conditions less than 12 hr light/ 12 hr dark cycle in the animal 
house. Animals are fed with commercial pellet diet and water ad libitum freely throughout 
the study. The experimental procedure was approved by IAEC (Institution of Animal 
Ethical Committee). 
3.4.1. EXPERIMENTAL DESIGN FOR MPTP INDUCED PARKINSON 
Group Number of animals Group Specifications 
 
Group I 
 
6 
 
Vehicle control (normal saline 
i.p) 
Group II 6 Only MPTP (25 mg/kg, i.p) 
 
Group III 
 
6 
 
MPTP + Standard [Levodopa 12 
mg/kg + Benzerazide 3mg/kg  
i.p] 
 
Group IV 
 
6 
 
MPTP + AEBP (200 mg/kg, p.o) 
 
Group V 
 
6 
 
MPTP + AEBP (400 mg/kg, p.o) 
Table 3 : Experimental design for MPTP induced Parkinson 
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Table 4 : Selection of animal for ROTENONE induced Parkinson evaluation 
Species Sprague-Dawley 
Age 50 days 
Body weight 80-100 
Gender Male 
No: of animals 30 
 
Male Sprague- Dawley rats 50 days of age, and 80-100 g body weight were offered by 
KMCH College of Pharmacy, Coimbatore. All the rats were kept at room temperature and 
allowed to acclimate in standard conditions less than 12 hr light/ 12 hr dark cycle in the 
animal house. Animals are fed with commercial pellet diet and water ad libitum freely 
throughout the study. The experimental procedure was approved by IAEC (Institution of 
Animal Ethical Committee). 
3.4.2. EXPERIMENTAL DESIGN FOR ROTENONE INDUCED PARKINSON 
Group Number of animals Group Specifications 
 
Group I 
 
6 
 
Vehicle control (normal saline i.p) 
 
Group II 6 
Only ROTENONE (3 mg/kg, i.p) 
 
 
Group III 
 
6 
 
ROTENONE + Standard [Levodopa 
12 mg/kg + Benzerazide 3mg/kg  
i.p] 
 
Group IV 
 
6 
 
ROTENONE + AEBP (200 mg/kg, 
p.o) 
 
 
Group V 
 
6 
 
ROTENONE + AEBP (400 mg/kg, 
p.o) 
 
Table 4 : Experimental design for Rotenone induced Parkinson 
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3.4.3 Induction of Parkinson
[72,73] 
 
Preparation and induction of MPTP solution 
            The MPTP was purchased from sigma chemicals, Mumbai, India and was stored 
according to the manufacturer label (37
0
C) to prevent its decomposition. The MPTP solution 
was freshly prepared at 25 mg/kg. The MPTP was dissolved in 0.9% sodium chloride 
solution and   injected i.p at the dose of 25 mg/kg body weight, 7 days. MPTP solution is 
stable only for a period of 24 hours at 4
0
C.  
Preparation and induction of ROTENONE solution 
            The Rotenone was purchased from sigma chemicals, Mumbai, India and was stored 
according to the manufacturer label (-20
0
C) to prevent its decomposition. The Rotenone 
solution was freshly prepared at 3 mg/kg. The Rotenone was dissolved in DMSO and adjust 
to pH 7.4 with potassium hydroxide. Rotenone  injected i.p at the dose of 3 mg/kg body 
weight, 7 days. The solution should be used immediately after preparation. Rotenone 
solution is stable only for a period of 24 hours at 25
0
C.  
Preparation of Levodopa and Benzerazide 
            12mg/kg of levodopa and 3 mg/kg of Benzerazide was dissolved in distilled water. 
Levodopa and benzerazide was freshly prepared daily and given via i.p to the standard group.  
Preparation of sample 
            200 mg/kg and 400 mg/kg were dissolved in distilled water and it was prepared 
freshly and given via oral route to group IV& V respectively for 7 days. 
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3.5. EVALUATION PARAMETERS 
3.5.1. MOTOR CO-ORDINATION TEST (ROTA ROD TEST) 
Principle  
The rota rod performance test is carried out on a rotating rod that provides forced motor 
activity in animals. The animals were placed on a rotating rod which is placed horizontally, 
suspended above a cage floor, which is high enough to induce avoidance of fall. Animals 
naturally try to stay on the rotating rod avoid falling to the ground. The length of time 
(duration) the animal stay on the rod without falling, gives a measure of their coordination, 
balance, physical condition and motor-planning.
[74]
  
Procedure  
Motor Co-ordination test was conducted using rota rod apparatus. Animal was placed 
individually on the rotating rod and trained for 3 min trail at 25 rpm on the day before the 
first day of testing. A cut off time of 180s was fixed and each animal performed 3 separate 
trials at 5 min interval. After each trial, 5 min rest period was given to alleviate stress and 
fatigue. Motor coordination can be tested by comparing the latency to fall on the very first 
trial between treatment groups. The time taken by animals to  fall from the rotating rod was 
noted.
[75]
 
 
3.5.2. LOCOMOTOR ACTIVITY 
Principle  
The locomotor activity (horizontal activity) can be easily measured using an actophotometer 
which operates on photoelectric cells which are connected in circuit with a counter. When the 
beam of light falling on the photocell is cut off by the animal, a count is recorded. An 
actophotometer could have either circular or square area in which the animal moves.
[76] 
 
Procedure  
The spontaneous locomotor activity of each animal was recorded individually, using 
Actophotometer. The apparatus was placed in a sound attenuated and ventilated room during 
the testing period. All the animals were placed individually in the activity cage for 3 min to 
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habituate them before starting actual locomotor activity task for the next 3 min. the basal 
activity score was noted. The units of the activity counts were arbitrary and based on the 
beam breaks by movement of the animal. Counts/3 min is used as an index of locomotor 
activity.
[77] 
 
 
3.5.3. FORCED SWIMMING TEST 
Principle  
Forced swimming test Is a behavioural despair test. This test is most widely used to assess 
alterations in depression-like behaviour in animals. The time spent by the animal as immobile 
in water represents the depression-like behaviour.
[78]
  
Procedure  
The test was performed according to the method described by Porsolt et al., 1977, with slight 
modifications. Animals were forced to swim in a glass cylinder (20 cm height, 14 cm 
diameter) containing 10 cm depth of water at 25ᵒ c. After the initial 2 min acclimatization 
period, the total duration of immobility was measured during final 4 min of the 6 min test 
session. Animal were considered to be immobile, when they made no further attempts to 
escape except the movements necessary to kept their heads above the water. After 6 min, the 
animals were removed from water, allowed to dry, and returned back to their home cage.
[79] 
 
 
3.5.4. HOLE BOARD TEST 
Principle  
When a animal is placed on the hole board apparatus, which is elevated to 25 cm from the 
base, shows anxiety as it is exposed to a new environment, thus showing characteristics head 
poking behaviour. Decrease in anxiety shows increased exploration of the holes. Whereas 
increased anxiety shows lower number of head poking.
[80] 
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Procedure  
The hole board apparatus consist of a wooden board (40*40cm) placed 25 cm above the 
ground. It consists of 16 holes which is about 3 cm in diameter, spaced symmetrically in a 
diamond pattern. Animals were placed on the corner of the apparatus and were observed for 
the next 5 min for the number of head dipping. A head dipping is counted when the animal 
introduces its head into any hole of the box up to the level of the ears. The apparatus was 
thoroughly cleaned between each subject.
[81] 
 
 
3.5.5. TAIL SUSPENSION TEST 
Principle  
The tail-suspension test (TST) is a widely used assay for screening potential antidepressant 
drugs. The test is based on the principle that animal subjected to the short-term, inescapable 
stress of being suspended by their tail, will develop an immobile posture.
[82]
 
 
Procedure  
The tail suspension test is another well characterized test for assessing depression-like and 
anti-depressant like  activity. In this test animal were individually suspended by the tail to a 
horizontal ring –stand bar ( distance from floor = 30cm ) using adhesive tape ( distance from 
tip of tail = 2cm ). Typically animal demonstrated several escape-orientated behaviours 
interspersed with temporally increasing bouts of immobility. A 6-mins test session was 
employed, which was videotaped. The parameter recorded was the number of seconds spent 
immobile.
[83]
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3.6. ESTIMATION OF BRAIN NEUROTRANSMITTER 
3.6.1. Estimation of Serotonin, GABA and Dopamine  
Preparation of tissue extracts 
Reagents  
 HCl – Butanol solution: (0.85 ml of 37% hydrochloric acid in one-litre n-butanol)  
 Heptane  
 M HCl: (0.85 ml conc. HCl up to 100 ml H2O)  
Procedure  
                   At the end of experiment, rats were sacrificed and the whole brain was dissected 
out. 0.25 g of tissue was weighed and was homogenized in 5 mL HCl–butanol with motor 
driven Teflon coated homogenizer for about 1 min. The sample was then centrifuged for 10 
min at 2000 rpm. An aliquot supernatant phase (1 mL) was removed and added to centrifuge 
tube containing heptane (2.5 mL) and 0.1 M HCl (0.31 mL). After 10 min of vigorous 
shaking, the tube was centrifuged under the same conditions as above in order to separate the 
two phases, and the overlaying organic phase was discarded. The aqueous phase was then 
taken either for 5-HT or NA and DA assay.  
3.6.2. Estimation of dopamine 
Reagents  
 0.4 M HCl: 0.34 ml conc. HCl up to 10 mL H2O 
 Sodium acetate buffer (pH 6.9): 0.72 mL of 1 M acetic acid (6 µL of glacial acetic acid 
up to 1000 µL with distilled water) + 6.84 mL of 0.3 M sodium acetate (0.408 g of 
sodium acetate in 10 mL distilled water) and volume were made up to 25 mL with 
distilled water. pH was adjusted with sodium hydroxide solution.  
 5 M sodium hydroxide: 5 g of NaOH pellets dissolved in distilled water and volume was 
made up to 25 mL with distilled water. 
 M Iodine solution (in Ethanol): 1 g of potassium iodide + 0.65 g of iodine dissolved in 
ethanol and volume was made up to 25 mL. 
 Sodium thiosulphate solution: 0.625 g Na2SO3 in 2.5 mL H2O + 22.5 mL 5 M NaOH 
 10 M Acetic acid: 14.25 mL of glacial acetic acid dissolved in distilled water and made 
up to 25 mL.   
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Procedure  
To 1 mL of aqueous phase, 0.25 mL 0.4 M HCl and 0.5 mL of Sodium acetate buffer (pH 6. 
9) were added followed by 0.5 mL iodine solution (0.1 M in ethanol) for oxidation. The 
reaction was stopped after 2 min by the addition of 0.5 mL Na2SO3 solution. 0.5 mL Acetic 
acid was added after 1.5 min. The solution was then heated to 100°C for 6 min.  When the 
sample reached room temperature, excitation and emission spectra were read from the 
spectrofluorimeter. The readings were taken at 330-375 nm for dopamine. Blanks for the 
assay were prepared by adding the reagents of the oxidation step in reversed order (sodium 
sulphite before iodine). Different concentration of dopamine and nor-adrenaline (1 mg/ml) 
was used as standard.
[84]
  
3.6.2. Estimation of Serotonin  
The serotonin content was estimated by the OPT method
 
Reagents  
O-phthaldialdehyde (OPT) reagent: (20 mg in 100 ml conc. HCl) 
Procedure  
To 1.4 mL aqueous extract, 1.75 mL of OPT reagent was added. The fluorophore was 
developed by heating to 100°C for 10 min. After the samples reached equilibrium with the 
ambient temperature, readings were taken at 360-470 nm in the spectrofluorimeter. 
Concentrated HCI without OPT was taken as blank. Serotonin (1 mg/mL) at different 
concentration was used as standard.
[85]
 
3.6.3. Estimation of brain GABA content
 
 
Preparation of tissue homogenate 
Animals were sacrificed by decapitation and the whole brain was rapidly removed. 0.5 g 
tissue was weighed and placed in 5 mL of ice-cold TCA (10% w/v). The tissue was then 
homogenized and centrifuged at 10,000 rpm for 10 min at 0°C. The supernatant was used for 
estimation of GABA content. 
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Reagents: 
 Carbonate-bicarbonate buffer, 0.5 M (pH 9.95): 1.0501 g sodium bicarbonate and 
1.3249 g sodium carbonate dissolved in distilled water and made up to 25 ml. pH 
adjusted to 9.95 if necessary. 
 0.14 M ninhydrin solution: 499 mg ninhydrin dissolved in 0.5 M carbonate-
bicarbonate buffer and made up to 20 ml. 
 Copper tartarate reagent: 0.16% disodium carbonate, 0.03% copper sulphate and 
0.0329% tartaric acid. 
 Procedure: 
0.1 mL of tissue homogenate was placed in 0.2 mL of 0.14 M ninhydrin solution in 0.5 M 
carbonate-bicarbonate buffer (pH 9.95), and kept in a water bath at 60°C for 30 min. It was 
then cooled and treated with 5 mL of copper tartarate reagent.  After 10 min fluorescence at 
377/455 nm in a spectofluorimeter was recorded. 
[86]
 
 
3.7 In vivo antioxidant activity 
3.7.1. Estimation of reduced glutathione (GSH)
  
  Requirements 
 10%TCA  
 0.6 mM 5, 5’-dithiobis-2-nitrobenzoic acid (DTNB) in 0.2 M sodium phosphate 
 0.2 M Phosphate buffer, pH 8.0 
Principle 
DTNB is a disulfide compound, which was reduced by sulphadryl groups present in GSH. 
This reduction leads to the formation of yellow color, which was measured at 412 nm.  
Procedure : To 1 ml of the homogenate, 1 ml of the TCA solution was added and 
centrifuged. The supernatant was collected and the precipitate formed was removed. To 0.5 
ml of supernatant 2 ml of DTNB was added, the volume was made up to 3 ml with phosphate 
buffer. Then absorbance was read at 412 nm. The amount of glutathione was expressed as 
µ/mg protein.
[87] 
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3.7.2. Determination of lipid peroxidation  
Requirements  
 Thiobarbituric acid 0.37 % 
 0.25 N HCl  
 15%TCA  
Principle  
This assay is based on the reduction of thiobarbituric acid with malonyl dialdehyde which is a 
formed as a result of polyunsaturated fatty acid oxidation. This reaction leads to the 
formation of pink colored TBA-MDA complex which is measured at 532 nm.  
Procedure: 
To 0.1 ml of sample, 2 ml of TBA-TCA-HCl reagent (ratio of 1:1) was added mixed and kept 
in a water bath for 15 minutes. Afterward the solution was cooled and supernatant was 
removed and absorbance was measured at 535 nm against reference blank. The level of lipid 
peroxides was given as nm moles of MDA formed/mg protein.
[88]
  
 
3.7.3 Estimation of proteins  
Requirements  
 Alkaline copper reagent  
 Solution A: 2% sodium carbonate in 0.1 N NaOH  
 Solution B: 0.5% copper sulphate in 1% sodium potassium tartarate .50 ml of solution      
A was mixed with 1 ml of solution B just before use.  
 Folin’s phenol reagent (commercial reagent, 1:2 dilutions),  
 Bovine serum albumin (BSA).  
Principle 
                       This method is a combination of both Folin-ciocalteau and biuret reaction which 
involves two steps 
Step: 1 Protein binds with copper in alkaline medium and reduces it to Cu++.  
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Step: 2 The cu++ formed catalyzes the oxidation reaction of aromatic amino acid by reducing 
phosphomolybdotungstate to heteropolymolybdanum ,which leads to the formation of blue 
color and absorbance was measured at 640 nm. 
Procedure: 
                  To 0.1 ml of the homogenate, 0.9 ml of water, 4.5 ml of alkaline copper sulphate 
reagent were added and allowed to stand at the room temperature for 10 minutes. To this 0.5 
ml of folin’reagent was added. After 20 minutes, the color developed was measured at 640 
nm. The level of protein present was expressed as mg/g/ tissue or mg/dl.
[89] 
  
  
     3.8. HISTOPATHOLOGY TECHNIQUES 
The brain was collected and washed under saline and preserved in 10% buffered formalin. 
The tissues were trimmed into sections and were subjected to prepare paraffin blocks. 5 
microns thickness sections were cut and stained with haematoxylin and eosin (H & E) and 
observed under the microscope.        
             
3.9. STATISTICAL ANALYSIS 
The statistical analysis was carried out by using PRISM version 5 software. The data’s of all 
parameters were analysed by means of one way ANOVA followed by Dunnett’s test. The 
results were expressed as mean ±SEM. 
. 
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4. RESULTS 
 
4.1. EXTRACTIVE YIELD 
Percentage Yield of AEBP 
Coarsely powdered whole plant of Barleria prionitis were extracted with water using 
maceration technique and the percentage yield was found to be 12% w/w. 
4.2. PRELIMINARY PHYTOCHEMICAL ANALYSIS 
Table 6 : Phytochemical analysis of AEBP 
 
S.NO 
 
PHYTOCHEMICAL 
CONSTITUENTS 
 
AEBP 
   1 Alkaloids Negative 
2 Flavonoids Present 
3 Steroids Negative 
4 Triterpenoids Present 
5 Reducing sugars Negative 
6 Tannins Present 
7 Glycosides Present 
8 Protein and Amino acids Negative 
9 Saponins Present 
10 Phenols Present 
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 4.3. SCREENING OF ANTIPARKINSONIAN ACTIVITY OF AEBP: 
[Rotenone Model] 
4.3.1. ROTA ROD TEST: 
Table 7 : Effect of AEBP on muscle grip strength 
 
Groups 
 
 
Time spent on Rota rod (sec) 
 
 
Day 3 
 
Day 5 
 
Day 7 
 
 
Vehicle control 
 
129±1.15 129±1.44 130±1 
 
ROTENONE 
 
 
 
69.667±1.20*** 
 
 
 
 
60±1.52*** 
 
 
 
43.333±9.98*** 
 
 
ROTENONE + 
Levodopa/benzerazide 
 
58±2.08*** 
 
81.333±1.20*** 
 
118.67±6.75*** 
 
 
ROTENONE + AEBP 
(200 mg/kg) 
 
47.667±2.603*** 
 
62.333±0.88*** 
 
 
95±7.48*** 
 
 
 
ROTENONE + AEBP 
(400 mg/kg) 
 
53±2.08*** 
 
76.333±6.634*** 
 
111.33±3.52*** 
 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. A aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control. 
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Figure 6 : Effect of AEBP on muscle grip strength- day 3 
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Figure 7 : Effect of AEBP on muscle grip strength- day 5 
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Rotarod-day-7
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Figure 8 : Effect of AEBP on muscle grip strength- day 7 
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4.3.2. ACTOPHOTOMETER TEST:- 
Table 8 :- Effect of AEBP on Spontaneous locomotor activity 
 
Groups 
 
 
Locomotive score (sec) 
 
 
Day 3 
 
Day 5 
 
Day 7 
 
 
Vehicle control 
 
392.33±4.46 412±2.08 396±1.15 
 
ROTENONE 
 
195.33±8.04*** 
 
173.33±1.85*** 
 
157.67±1.42*** 
 
 
ROTENONE + 
Levodopa/benzerazide 
 
176±1.16*** 
 
228.33±1.45*** 
 
258.33±2.42*** 
 
 
ROTENONE + AEBP 
(200 mg/kg) 
 
169±1.73*** 
 
198±5.13*** 
 
224.33±2.90*** 
 
 
ROTENONE +AEBP 
(400 mg/kg) 
 
178.33±2.02*** 
 
212.33±2.17*** 
 
246.33±2.18*** 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control.  
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Figure 9 : Effect of AEBP on locomotor activity - day 3 
 
Actophotometer-day-5
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Figure 10 : Effect of AEBP on locomotor activity - day 5 
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Actophotometer-day-7
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Figure 11 : Effect of AEBP on locomotor activity - day 7 
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4.3.3. FORCED SWIM  TEST:- 
Table 9 : Effect of AEBP on depression 
 
Groups 
 
 
 Immobility time (sec) 
 
 
Day 3 
 
Day 5 
 
Day 7 
 
 
Vehicle control 
 
55±4.22 
 
52±1.23 
 
 
53±1.94 
 
 
ROTENONE 
 
 
128.67±0.85*** 
 
 
 
130.33±2.40*** 
 
 
 
132.67±1.45*** 
 
 
ROTENONE + 
Levodopa/benzerazide 
 
125.33±1.36*** 
 
 
107.33±2.33*** 
 
 
 
90±1*** 
 
 
 
ROTENONE + AEBP 
(200 mg/kg) 
 
133.33±2.60*** 
 
 
125.33±4.45*** 
 
 
121.33±3.09*** 
 
 
ROTENONE +AEBP 
(400 mg/kg) 
 
135.67±0.09*** 
 
 
119.67±1.21*** 
 
 
99.667±1.22*** 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control.   
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Figure 12 : Effect of AEBP on depression by forced swim test- day 3 
 
Forced swim test-day-5
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Figure 13 : Effect of AEBP on depression by forced swim test- day 5 
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Forced swim test-day-7
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Figure 14 : Effect of AEBP on depression by forced swim test- day 7 
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4.3.4. TAIL SUSPENSION TEST:-    
Table 10 : Effect of AEBP on depression 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control.  
 
Groups 
 
 
 Immobility time (sec) 
 
 
Day 3 
 
Day 5 
 
Day 7 
 
 
Vehicle control 
 
58±0.89 54.333±1.45 55±4.46 
 
ROTENONE 
 
 
 
132.67±1.76*** 
 
 
 
135±1.52*** 
 
 
 
136±2.32*** 
 
 
 
ROTENONE + 
Levodopa/benzerazide 
 
 
127.33±1.85*** 
 
 
108.33±1.12*** 
 
92±2.30*** 
 
 
ROTENONE + AEBP 
(200 mg/kg) 
 
 
136.67±3.56*** 
 
 
 
126.67±0.75*** 
 
 
124±1.97*** 
 
 
ROTENONE +AEBP 
(400 mg/kg) 
 
132±1.33*** 
 
 
122.67±3.71*** 
 
 
 
102.67±2.78*** 
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Figure 15 : Effect of AEBP on depression by tail suspension test-day 3 
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Figure 16 : Effect of AEBP on depression by tail suspension test-day 5 
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Figure 17 : Effect of AEBP on depression by tail suspension test-day 7 
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4.3.5. HOLE BOARD  TEST:- 
Table 11 : Effect of AEBP on alertness 
 
Groups 
 
 
No. of head dippings 
 
 
Day 3 
 
Day 5 
 
Day 7 
 
 
Vehicle control 
 
32±3.06 32±4.52 
 
 
29±2.42 
 
 
 
ROTENONE 
 
21.667±1.76** 
 
20.333±2.95*** 
 
14±2.51*** 
 
 
ROTENONE + 
Levodopa/benzerazide 
 
23±1** 
 
23±1.73** 
 
27.333±0.66ns 
 
 
ROTENONE + AEBP 
(200 mg/kg) 
 
13.667±1.76*** 
 
12.667±0.43*** 
 
 
18.667±3.01*** 
 
 
 
ROTENONE +AEBP 
(400 mg/kg) 
 
16±0.08*** 
 
20.333±4.03*** 
 
23.333±0.31*** 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control.  
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Figure 18 : Effect of AEBP on depression by hole board test-day 3 
 
Hole board test-day-5
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Figure 19 : Effect of AEBP on depression by hole board test-day 5 
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Hole board test-day-7
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Figure 20 : Effect of AEBP on depression by hole board test-day 7 
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4.4. ESTIMATION OF TOTAL PROTEIN 
Table 12 : Effect of AEBP on total protein in brain tissue 
 
Groups 
 
 
TOTAL PROTEIN 
( mg/100mg of tissue ) 
 
 
Vehicle control 
 
5.43±0.16 
 
 
ROTENONE 
 
2.17±0.01*** 
 
 
ROTENONE+ Levodopa/benzerazide 
 
4.09±0.08*** 
 
 
ROTENONE + AEBP (200 mg/kg) 
 
2.8333±0.11*** 
 
 
ROTENONE +AEBP (400 mg/kg) 
 
3.8733±0.04*** 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed.  aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control. 
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Figure 21 : Effect of AEBP on total protein in brain tissue 
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4.5. IN VIVO ANTIOXIDANT STUDY 
Table 13 : Effect of AEBP on IN VIVO antioxidants of brain of ROTENONE induced 
parkinsonic mice 
 
Groups 
 
 
GSH (Glutathione µg/mg 
protein) 
 
 
LPO (nmol of MDA/mg 
protein) 
 
Vehicle control 
 
5.0733±0.043 
 
3.7267±0.012 
 
ROTENONE 
 
2.1267±0.027*** 
 
4.93±0.011*** 
 
 
ROTENONE + 
Levodopa/benzerazide 
 
4.39±0.026*** 
 
3.9217±0.003*** 
 
 
ROTENONE + AEBP 
(200 mg/kg) 
 
2.9233±0.035*** 
 
4.1167±0.017*** 
 
 
ROTENONE +AEBP 
(400 mg/kg) 
 
3.9833±0.020*** 
 
3.1067±0.008*** 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control. 
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Figure 22 : Effect of AEBP on GSH in brain tissue 
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Figure 23 : Effect of AEBP on LPO in brain tissue 
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4.6. ESTIMATION OF BRAIN NEUROTRANSMITTERS 
Table 14 : Effect of AEBP on brain neurotransmitters of ROTENONE induced 
parkinsonic rats 
 
Groups 
 
 
DOPAMINE(ng/g 
tissue) 
 
SEROTONINE(ng/g 
tissue) 
 
GABA(ng/g tissue) 
 
vehicle control 
 
373.33±0.06 379.33±0.88 213.67±2.31 
 
ROTENONE 
 
174.33±1.30*** 
 
189.67±1.16*** 
 
125.33±1.11*** 
 
 
ROTENONE + 
Levodopa/benzerazide 
 
292.67±1.66*** 
 
286.33±1.10*** 
 
154.33±1.22*** 
 
 
ROTENONE + AEBP 
(200 mg/kg) 
 
187.67±2.70*** 
 
205.67±0.42*** 
 
142.33±0.51*** 
 
 
ROTENONE +AEBP 
(400 mg/kg) 
 
228.67±1.32*** 
 
220.33±0.11*** 
 
155.33±1.76*** 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control. 
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Figure 24 : Effect of AEBP on dopamine in brain tissue 
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Figure 25 : Effect of AEBP on GABA in brain tissue 
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Figure 26 : Effect of AEBP on serotonin in brain tissue 
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4.7. SCREENING OF ANTIPARKINSONIAN ACTIVITY OF AEBP:- 
[ MPTP MODEL ] 
4.7.1. ROTA ROD TEST:- 
Table 15 : Effect of AEBP on muscle grip strength 
 
Groups 
 
 
Time spent on Rota rod (sec) 
 
 
Day 3 
 
Day 5 
 
Day 7 
 
 
Vehicle control 
 
178±0.57 179±1.48 178.67±0.95 
 
MPTP 
 
74.667±1.33*** 
 
62±0.26*** 
 
61.333±0.18*** 
 
MPTP+ Levodopa/benzerazide 
 
59±2.02*** 
 
84.667±1.76*** 
 
120.67±0.59*** 
 
 
MPTP + AEBP (200 mg/kg) 
 
47±1.52*** 
 
67±0.64*** 
 
94.667±0.72*** 
 
 
MPTP + AEBP (400 mg/kg) 
 
53.333±2.40*** 
 
81±2.08*** 
 
111.67±0.14*** 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control.  
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Figure 27 : Effect of AEBP on muscle grip strength- day 3 
 
 
Rotarod-day-5
C
O
N
TR
O
L
O
N
LY
 M
PT
P
M
PT
P+
ST
D
M
PT
P+
A
EB
P 
20
0
M
PT
P+
A
EB
P 
40
0
0
50
100
150
200
s
e
c
/m
in
 
Figure 28 : Effect of AEBP on muscle grip strength- day 5 
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 Figure 29 : Effect of AEBP on muscle grip strength- day 7 
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4.7.2. ACTOPHOTOMETER TEST: 
Table 16 :- Effect of AEBP on Spontaneous locomotor activity 
 
Groups 
 
 
Locomotive score (sec) 
 
 
Day 3 
 
Day 5 
 
Day 7 
 
 
Vehicle control 
 
384±3.60 
 
394±1.15 
 
 
386.33±1.56 
 
 
MPTP 
 
 
186±2.30*** 
 
 
 
162.67±2.02*** 
 
 
 
 
145.33±0.23*** 
 
 
 
MPTP+ Levodopa/benzerazide 
 
166.33±2.60*** 
 
 
217.33±0.02*** 
 
 
 
246.33±0.77*** 
 
 
 
MPTP + AEBP (200 mg/kg) 
 
 
155.33±1.48*** 
 
 
 
184.67±0.91*** 
 
 
 
 
215.67±0.56*** 
 
 
 
MPTP +AEBP (400 mg/kg) 
 
 
162±1.55*** 
 
 
 
198±1.12*** 
 
 
 
 
236.67±1.85*** 
 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control.  
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Figure 30 : Effect of AEBP on locomotor activity - day 3 
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Figure 31 : Effect of AEBP on locomotor activity - day 5 
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Figure 32 : Effect of AEBP on locomotor activity - day 7 
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4.7.3. FORCED SWIM  TEST: 
Table 17 : Effect of AEBP on depression 
 
Groups 
 
 
Total immobility time (sec) 
 
 
Day 3 
 
Day 5 
 
Day 7 
 
 
Vehicle control 
 
52.333±2.60 47.667±0.93 48.667±1.33 
 
MPTP 
 
 
125±0.73*** 
 
 
130.33±1.76*** 
 
 
131.33±2.37*** 
 
 
MPTP+ Levodopa/benzerazide 
 
 
117.67±0.06*** 
 
 
101±1.15*** 
 
 
85.333±1.78*** 
 
 
 MPTP + AEBP (200 mg/kg) 
 
 
127.67±2.85*** 
 
 
120.67±0.89*** 
 
 
118.67±2.27*** 
 
 MPTP +AEBP (400 mg/kg) 
 
 
  127±1.01*** 
 
 
116.33±3.74*** 
 
93.333±0.15*** 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control. 
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Figure 33 : Effect of AEBP on depression by forced swim test- day 3 
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Figure 34 : Effect of AEBP on depression by forced swim test- day 5 
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Figure 35 : Effect of AEBP on depression by forced swim test- day 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
Department of Pharmacology, KMCH College of Pharmacy 81 
 
4.7.4. TAIL SUSPENSION TEST :- 
Table 18 : Effect of AEBP on depression 
 
Groups 
 
 
Immobility time (sec) 
 
 
Day 3 
 
Day 5 
 
Day 7 
 
 
Vehicle control 
 
54.667±1.29 52.667±1.85 53±1.52 
 
MPTP 
 
129.67±3.33*** 
 
132.67±0.04*** 
 
131±2.47*** 
 
 
MPTP+ Levodopa/benzerazide 
 
123±2.08*** 
 
103.67±1.66*** 
 
87.667±0.18*** 
 
 
MPTP + AEBP (200 mg/kg) 
 
132.67±0.36*** 
 
123.33±1.45*** 
 
121.33±4.93*** 
 
 
MPTP +AEBP (400 mg/kg) 
 
128.33±2.12*** 
 
118.33±1.48*** 
 
96±0.83*** 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control.  
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Figure 36 : Effect of AEBP on depression by tail suspension test- day 3 
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Figure 37 : Effect of AEBP on depression by tail suspension test- day 5 
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Figure 38 : Effect of AEBP on depression by tail suspension test- day 7 
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4.7.5. HOLE BOARD  TEST:- 
Table 19 : Effect of AEBP on alertness 
 
Groups 
 
 
No. of head dippings 
 
 
Day 3 
 
Day 5 
 
Day 7 
 
 
Vehicle control 
 
36±1.31 
 
36±0.14 
 
33.667±2.46 
 
 
MPTP 
 
22±3.68*** 
 
 
22.333±1.79** 
 
 
18.333±4.82*** 
 
 
 
MPTP+ Levodopa/benzerazide 
 
23±1.67*** 
 
24±2.09** 
 
31.333±0.88ns 
 
 
MPTP + AEBP (200 mg/kg) 
 
18.333±3.36*** 
 
18±1.73*** 
 
 
21.333±0.91*** 
 
 
 
MPTP +AEBP (400 mg/kg) 
 
23.333±4.55*** 
 
24.333±2.52** 
 
 
27.333±1.20* 
 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control.   
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Figure 39 : Effect of AEBP on depression by hole board test-day 3 
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Figure 40 : Effect of AEBP on depression by hole board test-day 5 
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Figure 41 : Effect of AEBP on depression by hole board test-day 7 
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4.8. ESTIMATION OF TOTAL PROTEIN 
Table 20 : Effect of AEBP on total protein in brain tissue 
 
Groups 
 
 
TOTAL PROTEIN 
( mg/100mg of tissue ) 
 
 
Vehicle control 
 
3.3533±0.0202 
 
MPTP 
 
4.4533±0.0133*** 
 
 
MPTP+ Levodopa/benzerazide 
 
3.8267±0.0088*** 
 
 
MPTP + AEBP (200 mg/kg) 
 
4.0833±0.0437*** 
 
 
MPTP +AEBP (400 mg/kg) 
 
3.6067±0.0352*** 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control.  
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Figure 42 : Effect of AEBP on total protein in brain tissue 
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4.9. IN VIVO ANTIOXIDANT STUDY 
Table 21 : Effect of AEBP on IN VIVO antioxidants of brain of MPTP induced 
parkinsonic mice. 
 
Groups 
 
 
GSH (Glutathione µg/mg 
protein) 
 
 
LPO (nmol of MDA/mg 
protein) 
 
Vehicle control 
 
6.4933±0.0014 
 
6.1547±0.0588 
 
MPTP 
 
2.34±0.0556*** 
 
11.436±0.0067*** 
 
 
MPTP+ 
Levodopa/benzerazide 
 
4.225±0.0565*** 
 
7.2437±0.0014*** 
 
 
MPTP + AEBP (200 mg/kg) 
 
3.2367±0.0638*** 
 
9.055±0.0062*** 
 
 
MPTP +AEBP (400 mg/kg) 
 
4.1457±0.0560*** 
 
7.5247±0.0075*** 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control.  
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Figure 43 : Effect of AEBP on GSH in brain tissue 
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Figure 44 : Effect of AEBP on LPO in brain tissue 
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4.10. ESTIMATION OF BRAIN NEUROTRANSMITTERS 
Table 22 : Effect of AEBP on brain neurotransmitters of MPTP induced parkinsonic 
mice 
 
Groups 
 
 
DOPAMINE (ng/g 
tissue) 
 
SEROTONINE(ng/g 
tissue) 
 
GABA(ng/g 
tissue) 
 
Vehicle control 
 
367.67±11.28 
 
357.67±2.84 
 
203±1.52 
 
 
MPTP 
 
188±1.41*** 
 
174.33±3.45*** 
 
109.33±2.49*** 
 
MPTP+ 
Levodopa/benzerazide 
 
287±5.50*** 
 
273±2.08*** 
 
142±0.03*** 
 
 
MPTP + AEBP  
(200 mg/kg) 
 
198.33±4.33*** 
 
192.67±0.58*** 
 
128.33±1.85*** 
 
 
MPTP +AEBP  
(400 mg/kg) 
 
217±2.30*** 
 
206±4.46*** 
 
138.67±1.33*** 
 
 
Statistical comparison: Each group (n=6), each value represents Mean ± SEM. One way 
Anova followed by Dunnett’s test was performed. aP<0.001 denotes comparison of 
parkinsonic control with vehicle control and ns- non significant 
*
P<0.05, 
**
P<0.01, and 
***
P<0.001 denotes comparison of all groups with parkinsonic control. 
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             Figure 45 : Effect of AEBP on dopamine in brain tissue 
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                Figure 46 : Effect of AEBP on GABA in brain tissue 
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               Figure 47 : Effect of AEBP on serotonin in brain tissue 
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HISTOPATHOLOGICAL EVALUATION MPTP INDUCED PARKINSONISM 
   
                                    10X                                                                   40X 
                                                      VEHICLE CONTROL 
 From the results the Mice brain cerebral cortex shows normal morphology. And 
shows neurons are normal in number and morphology surrounding parenchyma shows 
normal histology. The molecular purkinjiec layer shows normal. There is no evidence of 
neuronal degeneration/inflammation. 
 
 
   
                                    10X                                                                   40X 
 ONLY MPTP (20 mg/kg) 
 From the results the Mice brain cerebrum shows focal neuronal injury. Also show 
mononuclear inflammatory infiltration in the brain parenchyma with mild alter in the 
morphology and number of neurons. The molecular purkinjiec layer shows normal 
morphology. 
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10X                MPTP+ LEVODOPA/BENZERAZIDE           40X 
 From the results Mice brain with cerebellum and cerebral cortex shows degeneration. 
Hippocampus shows atrophy. Para hippocampal cortex shows degeneration and mild gliosis. 
Section from cerebrum shows sclerosis and degeneration. Thalamus, amygdale and substantia 
nigra shows no significant pathology. 
    
10X                   MPTP+ AEBP (200mg/kg)               40X 
 From the results the Mice brain with cerebellum and cerebral cortex shows 
degeneration. Hippocampus shows atrophy. Para hippocampal cortex shows degeneration and 
mild gliosis. Section from cerebrum shows sclerosis and degeneration. Thalamus, amygdale 
and substantia nigra shows no significant pathology. 
   
10X                           MPTP+ AEBP (400mg/kg)                         40X 
 From the results the Mice brain with cerebellum shows normal molecular purkinjiec cell 
layers. Hippocampus shows gliosis and degeneration. Section from cerebral cortex shows severe 
gliosis and degeneration. Corpus striatum, thalamus and amygdala shows no significant pathology. 
Substantia nigra  and choroid plexus are no significant pathology. 
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   HISTOPATHOLOGICAL EVALUATION ROTENONE INDUCED 
PARKINSONISM 
            
          10x                       ROTENONE   + AEBP (200mg/kg)                      40x  
            From the results the Rat brain with cerebrum shows mild gliosis. Hippocampus shows 
normal granular and pyramidal cell layer. There is no disorganization/ degeneration are seen. 
Section from cerebellum shows no significant pathology (normal molecular, granular and 
purkinjiec layers). Parahippocampal cortex shows mild gliosis.  Thalamus and amygdala 
shows no significant pathology. 
      
                
             10x                       ROTENONE   + AEBP (200mg/kg)                  40x  
 
                     From the results the Rat brain with cerebellum shows normal normal molecular 
purkinjiec cell layers. Hippocampus shows mild gliosis and vacuolar degeneration. Section 
from cerebrum shows mild gliosis. Corpus striatum also shows mild gliosis. Thalamus and 
amygdala shows no significant pathology. Mild frontal cerebral cortex gliosis are seen. 
Substantia nigra  and choroid plexus are no significant pathology. 
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 5. DISCUSSION 
 This study aims to investigate the Neuroprotective effect of Barleria prionitis on MPTP 
and Rotenone intoxicated animal models of PD by analyzing behavior patterns, brain 
antioxidant, brain neurotransmitters and Histopathological studies. PD is a commonly occurring 
neurodegenerative disorder that produces muscular rigidity, bradykinesia, tremor in resting limbs 
and loss of postural balance. The basic neuropathology of PD involves the selective degeneration 
of dopaminergic cells in specific brain regions like the striatum; when degeneration in these 
neurons reaches a threshold reduction of 80% dopamine, the motor symptoms of PD emerge. 
The cerebral cortex, which is abundant with neurons and easily accessible, demonstrates its 
importance in modelling PD.  
 Barleria prionitis has a long history in herbal medicine in various countries. The leaves 
and bark of Barleria prionitis have long been used as a natural medicine in tropics. The bark and 
leaf extract of Barleria prionitis is well known for its different types of pharmacological 
properties such as Stomach disorder, Urinary infections, fever, Tooth ache, Diuretic, Jaundice, 
Asthma, Arthritis, Inflammation, Migraine, Dropsy, Leprosy. The major active constituents are 
Iridoids, Barlerin, Acetyl barlerin, β-sitosterol, Prioniside, Barlerinoside, verbascoside, 7-
methoxy diderroside, Anthroquinones, Flavonoids. Since Barleria prionitis have not been 
studied for its anti-parkinson activity, the present study was aimed to evaluate the anti-parkinson 
activity potential of aqueous extracts of Barleria prionitis in MPTP and rotenone induced swiss 
albino mice and SD rats respectively. 
 
MPTP was adapted as a PD model in rodents and primates. These studies showed that 
this compound acts as a lipophilic protoxin that crosses the BBB and is converted to the toxic 
metabolite 1-methyl-4-phenylpyridinium (MPP+) by astrocytes and serotonergic neurons
[90]
 by 
monoamine oxidase-B
[91]
. MPP+ is then released into the extracellular space and accumulated by 
the DA transporter (DAT) into DA neurons, causing a bilateral degeneration of the nigrostriatal 
tract
[92]
. MPP+ produces neurodegeneration through the blockade of electron transport chain 
enzyme complexes I, III, and IV
[93]
. Additional factors modulate MPTP toxicity including iron, 
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expression of the vesicular monoamine transporter, reactive oxygen species (ROS), and 
apoptosis
[94,95]
. 
 Exposure to the pesticide rotenone is linked to an increased risk of PD in epidemiological 
studies
[96,97,98]
, and have been adapted for PD models. Rotenone is highly lipophilic and crosses 
the BBB to diffuse into neurons where it inhibits complex I of the mitochondrial respiratory 
chain and causes neurodegeneration of SN neurons; however, reports of its selectivity for 
neurotoxicity are variable
[100]
.  
 
Effect of Barleria prionitis on MPTP and Rotenone-induced PD:   
Effect on behavioral parameters 
  Actophotometer is used for screening the locomotor and anti-anxiety activity in 
rodents, while the rotarod for muscle relaxant activity. Locomotor activity indicates attentiveness 
and the decline indicates sedative action. The GABA receptor compound is concerned in 
sedation, muscle relaxant and anxiety in CNS. Various neurological and mental disorders such as 
epilepsy, depression, Parkinson syndrome, Alzheimer’s disease are involved with this receptor. 
 The increase in locomotor activity OF extract of Barleria prioitis has shown stimulant effect in 
actophotometer. This provoked to evaluate it further, using paradigms of depression models. 
From the results the Actophotometer readings (locomotor activity) of animals of vehicle-treated 
control group (Group I) was found to be 386.33±1.56 and 396±1.15 counts/5 min for all 7 days 
of treatment. 
            MPTP and Rotenone treatment to animals of Group II showed a significant 
reduction in locomotor activity every week. The actophotometer readings decreased to 186±2.30 
and 195.33±8.04 counts/ 5 min. on the 7th day, went down to 145.33±0.23 and 157.67±1.42 
counts/5 min. Thus, there was a significant decline in the locomotor activity of rotenone treated 
control animals (Group III) when compared to vehicle-treated control group (Group I). 
  Treatment and Pretreatment with standard drug, Barleria prionitis (Group 
III,IV,V) produced a significant increase in locomotion (246.33±0.77, 215.67±0.56, 
236.67±1.85s and 258.33±2.42, 224.33±2.90, 246.33±2.18 counts/ 5 min.) on the 7th day of 
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treatment; as compared to the MPTP and Rotenone treated control (Group II) animals on the 
respective days. 
   
  Rota rod test a standard animal model used to evaluate peripheral neuromuscular 
blockade and the motor coordination, a deficit in motor coordination would very likely affect 
performance in the behavioral tests. Rota rod test, the difference in the fall of time from the 
rotating rod between the vehicle and extract treated groups were taken as an index of muscle 
relaxation.From the results the  Rota rod readings (fall off time) of Vehicle-treated Control group 
(Group I) animals from the rota rod was found to be 178.67±0.96 and 130±1s. MPTP and 
Rotenone treatment to animals of Group II showed a significant reduction in the muscle grip or 
strength every week. The rotarod fall off times decreased to 74.667±1.33 and 69.667±1.20s. 
counts/5 min. on the 7th day, went down to 61.333±0.18 and 43.333±9.98s counts/5min. Thus, 
there was a significant decrease (p<0.001) in the muscle activity of MPTP and Rotenone treated 
control animals (Group II) when compared to vehicle treated control group (Group I). 
  Treatment and Pretreatment with standard drug, Barleria prionitis (Group 
III,IV,V)  produced significantly increased the muscle activity (120.67±0.59, 94.667±0.72, 
111.67±0.14s and 118.67±6.75, 95±7.48, 111.33±3.52 ) on the 7th day of treatment; as compared 
to the MPTP and Rotenone -treated control (Group II) animals on the respective days. 
  Due to their immobility time, muscular coordination skill memory, motor 
impairment, retention times were also decreased. From the results the Tail suspension test 
readings (total immobility time) of Vehicle-treated Control group (Group I) animals was found 
to be 53±1.52 and 55±4.46s. MPTP and Rotenone treatment to animals of Group II showed a 
significant increase in the immobility time  every week. The tail suspension immobility times 
increased to 129.67±3.33 and 132.67±1.76s. sec/6 min. on the 7th day, went up to 131±2.47 and 
136±2.32s sec/6min. Thus, there was a significant increase (p<0.001) in the immobility time of 
MPTP and Rotenone treated control animals (Group II) when compared to vehicle treated 
control group (Group I). 
  Treatment and Pretreatment with standard drug, Barleria prionitis (Group 
III,IV,V)  produced significantly decreased the muscle activity (87.667±0.18, 121.33±4.93, 
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96±10.83 and 92±2.30, 124±1.97, 102.67±2.78 s) on the 7th day of treatment; as compared to the 
MPTP and Rotenone -treated control (Group II) animals on the respective days. 
  Forced swimming test  readings (total immobility time) of Vehicle-treated Control 
group (Group I) animals was found to be 48.667±1.33 and 53±1.94s. MPTP and Rotenone 
treatment to animals of Group II showed a significant increase in the immobility time  every week. 
The immobility times increased to 125±0.73 and 128.67±0.85 s. sec/6 min. on the 7th day, went up 
to 131.33±2.37 and 132.67±1.45s sec/6min. Thus, there was a significant increase (p<0.001) in the 
immobility time of MPTP and Rotenone treated control animals (Group II) when compared to     
vehicle treated control group (Group I). Treatment and Pretreatment with standard drug, Barleria 
prionitis (Group III,IV,V) produced significantly decreased the muscle activity (85.333±1.78, 
118.67±2.27, 93.333±0.15s and 90±1, 121.33±3.09, 99.667±1.22) on the 7th day of treatment; as 
compared to the MPTP and Rotenone -treated control (Group II) animals on the respective days. 
The hole board test is helpful for modeling anxiety in animals, in this test an anxiolytic-
like state may be reflected by an increase in head –dipping behaviors.  From the results the Hole 
board test readings (No.of head dippings) of Vehicle-treated Control group (Group I) animals 
was found to be 33.667±2.46 and 29±2.42. MPTP and Rotenone treatment to animals of Group 
II showed a significant decrease in the head dippings  every week. The hole board test head 
dipping decreased to 22±3.68 and 21.667±1.76 sec/5 min. on the 7th day, went up to 
18.333±4.82s and 14±2.51 sec/5min. Thus, there was a significant decrease (p<0.001) in the 
head dipping of MPTP and Rotenone treated control animals (Group II) when compared to 
vehicle treated control group (Group I).Treatment and Pretreatment with standard drug, Barleria 
prionitis (Group III,IV,V)  produced significantly increased the head dipping (31.333±0.88, 
21.333±0.91, 27.333±1.20 and 27.333±0.66, 18.667±3.01, 23.333±0.31) on the 7th day of 
treatment; as compared to the MPTP and Rotenone -treated control (Group II) animals on the 
respective days. 
Effect on Brain antioxidant levels 
  The biotransformation of MPTP into MPP+, which is catalyzed by the 
mitochondrial enzyme monoamine oxidase B, represents the major route for MPTP-mediated 
neurotoxicity
[101]
. The conversion of MPTP to MPP+ has been suggested to induce the formation 
Discussion  
 
Department of Pharmacology, KMCH College of Pharmacy  101 
 
of ROS. This notion is supported by previous studies which showed increased superoxide (O2∙−) 
and hydroxyl radical (∙OH) levels during the biotransformation of MPTP[102]. While the damage 
induced by O2∙− is limited, it can react with nitric oxide (NO) to form peroxynitrite (ONOOO−) 
which readily forms the more reactive ∙OH radical. Other studies have shown that MPTP induces 
toxicity through ATP depletion and mitochondrial dysfunction. Moreover, that ATP depletion 
plays a major role in MPTP induced neuronal cell death 
[103]
. However, it is likely that MDA can 
form complexes with other biological components such as protein, lipids, and nucleic acids 
which can contribute to an underestimation of endogenous lipid peroxidation
[104]
. On the 
contrary to our lipid peroxidation data, we also show that MPTP can lead to distinct alterations in 
endogenous antioxidant defense mechanisms. MPTP treatment has been previously shown to 
significantly increase Mn-SOD and CuZn-SOD activities in the striatum of C57BL/6 mice, 
which is suggestive of acute oxidative stress insult
[105]
. SOD is upregulated in cells when O2 ∙− 
is produced in excessive levels
[106]
. This observation suggests that SOD may play a role in the 
toxicity observed following acute treatment of MPTP, although ROS formation may not play a 
major role in MPTP-induced toxicity. CAT is an enzyme that is involved in the detoxification of 
ROS and the elimination of hydrogen peroxide (H2O2) in particular
[107]
. The increase in both 
intracellular SOD and CAT activities may therefore represent an adaptive response due to the 
leakage of free radicals during impaired mitochondrial respiration. Treatment with MPTP also 
leads to reduced activity of GPx and decreased levels of the essential pyridine nucleotide NAD+, 
ATP, and GSH in primary human neurons after a 24-hour exposure. The maintenance of GPx 
activity appears crucial for the maintenance of cell viability during oxidative insult 
[108-111]
. 
Moreover, previous studies have shown that MPP+, the metabolite of MPTP induces GSH 
depletion without increasing the levels of oxidized glutathione disulfide (GSSG)
 [112]
. Reduced 
GSH levels may occur due to that MPP+ induced decline in intracellular NAD+ and ATP stores 
which are necessary for GSH anabolism, release, and taken together, our data suggests that 
MPTP exposure can limit the endogenous antioxidant defense, subsequently increasing the 
vulnerability of neuronal cells to additional oxidative stress. An imbalance in the function of 
endogenous antioxidant defense mechanisms can lead to the accumulation of free radicals and 
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ROS and increased susceptibility to oxidative stress, which contributes to the pathogenesis of 
PD. 
Effect of Barleria prionitis on LPO level in brain: 
  The LPO level in Control group (Group I) animals was found to be 6.1547±0.05 
and 3.7267±0.01nmoles of MDA/mg protein. Administration of MPTP and Rotenone (Group II) 
resulted in a significant increase in LPO level in brain of animals as compared to Control group 
(Group I). Treatment and Pretreatment with standard drug, Barleria prionitis (Group III,IV,V) 
showed a significant reduction in the level of LPO in brain as compared to MPTP and Rotenone 
treated animals (Group III). 
Effect Barleria prionitis on GSH level of brain: 
  The level of GSH in the brain homogenate of Vehicle treated Control group 
(Group I) animals was found to be 6.4933±0.001and 5.0733±0.04μg/mg protein. MPTP and 
Rotenone treatment resulted in a significant decrease in GSH levels in brain of Group II animals 
as compared to control group (Group I). Treatment and Pretreatment with standard drug, 
Barleria prionitis (Group III,IV,V) significantly increased GSH levels in the brain as compared 
to MPTP and Rotenone treated animals (Group III) thus preventing the reduction in GSH 
induced by rotenone.  
Effect on Brain Neurotransmitters levels 
 MPTP selectively damages the dopaminergic nigrostriatal system, resulting in the loss of 
dopaminergic neurons in the substantia nigra and a depletion of dopamine in the striatum
[113]
.  
The loss of dopaminergic neurons is associated with an onset of motor symptoms, and there is a 
direct relationship between extent of dopamine loss and motor dysfunction 
[114]
. The striatum is 
considered to be the region responsible for head and forelimb motor control. Many studies have 
revealed impaired behavioural responses within a short span of MPTP lessoned animals
[115]
. The 
neurotransmitter, DA plays a key role in body movement and motor control. A well known fact 
is that there is a reduced level of Dopamine occurring in dopaminergic neuronal damaged brain 
[116]
. Dopamine neurotransmitter was more affected in Parkinson’s disease [117,118]where as other 
brain amines like norepinephrine, epinephrine and serotonin were much less affected than 
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dopamine in MPTP treated group
[119]
, because main targeted neurotransmitter is dopamine in 
Parkinson’s disease. These findings are near to previously reported study[120]. 
Estimation of dopamine assay 
 The MPTP and Rotenone treated group of animals had decreased dopamine levels when 
compared to the control group. Treatment and Pretreatment with standard drug, Barleria 
prionitis (Group III,IV,V) the dopamine activity showed significance increased in (p<0.001, 
p<0.01) on comparsion with the MPTP and Rotenone treated group shown as Table 21 and 14 . 
The data showed that the Barleria prionitis has a very protective role of dopamine in the receptor 
binding density of mice with Barleria prionitis. 
Estimation Serotonin 
The MPTP and Rotenone treated group of animals had decreased Serotonin levels when 
compared to the control group The serotonin activity was observed in the MPTP and Rotenone 
group mice when compared to the control group (p<0.01). Treatment and Pretreatment with 
standard drug, Barleria prionitis (Group III,IV,V) groups showed significance increase in 
Serotonin levels (p<0.001, p<0.01) when compared with the MPTP and Rotenone group shown 
in Table 21 and 14 . 
Estimation of GABA 
Table 21 and 14. depicts that the effect of Gamma –amino butyric acid levels decrease  in 
MPTP and Rotenone treated group of animals when compared to the control group group 
(p<0.001) .Whereas Treatment and Pretreatment with standard drug, Barleria prionitis (Group 
III,IV,V) treated mice was observed significance increase decreased (p<0.001, p<0.01) as 
compared with MPTP group. 
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6. CONCLUSION 
 
From the present study, it can be considered that the aqueous extract of Barleria prionitis 
exhibited significant anti-parkinsonism activity in MPTP and rotenone model in mouse and 
rats respectively. The probable mode of action of this plant decreased lipid peroxidation due 
to the presence of flavonoids, polyphenols and glycosides. All the Parameters of extract 
treated group animals have shown better results when  compared with  MPTP and Rotenone-
induced group and the standard L-dopa treated group.  These findings provide a preliminary 
evidence for its potential as anti-parkinsonian medication, including Parkinson’s disease 
prevention and improvement of symptoms.  
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